EIN Presswire: GlaxoSmithKline Live Feed Press Releases

Siemens Forms New Companion Diagnostics Partnerships with ViiV Healthcare and Tocagen

Tue, 07 Feb 2012 16:33:24 +0000

Siemens Forms New Companion Diagnostics Partnerships with ViiV Healthcare and Tocagen

Siemens' move into the companion diagnostics market targets the development of novel diagnostics tests for physicians treating HIV and brain cancer

PR Newswire

RESEARCH TRIANGLE PARK, N.C., SAN DIEGO and TARRYTOWN, N.Y., Feb. 7, 2012 /PRNewswire/ -- Siemens Healthcare Diagnostics announces two new companion diagnostics partnerships with pharmaceutical companies ViiV Healthcare and Tocagen — marking a major step for Siemens (NYSE: SI) into this important and fast-growing segment of the in vitro diagnostics (IVD) market. Both partnerships intend to leverage the clinical trial and commercialization options within Siemens' CLIA laboratory, as well as Siemens' established IVD clinical and regulatory expertise.

(Logo: http://photos.prnewswire.com/prnh/20070904/SIEMENSLOGO )

Siemens' partnership with ViiV Healthcare will focus on clinical trials related to Celsentri/Selzentry® (maraviroc) — ViiV Healthcare's novel CCR5 co-receptor antagonist for the treatment of CCR5-tropic HIV — followed by potential commercialization of a diagnostics test to assist in patient selection prior to physician treatment decisions, subject to FDA approval. According to the World Health Organization, 33.3 million people worldwide were living with HIV as of 2009. That same year, 2.6 million new infections were reported and 1.8 million people worldwide died of AIDS-related illnesses.

The Siemens - Tocagen relationship will begin with diagnostic tests to support clinical trials related to Tocagen's unique viral gene therapy (Toca 511 & Toca FC) under investigation for the treatment of primary brain cancer, followed by potential commercialization of diagnostic tests for therapy monitoring, subject to FDA approval. According to the American Cancer Society, primary brain and central nervous system cancers are expected to account for 22,910 new cases and 13,700 deaths in 2012. Additionally, the National Institutes of Health estimates that 10-30% of all adults with cancer will develop brain metastases.

Widely considered a major step towards the vision of personalized healthcare, companion diagnostics are clinical tests linked to a specific drug or therapy intended to assist physicians in making treatment decisions for their patients. The technology and science behind the field allows pharmaceutical drug developers to identify subpopulations of patients more or less likely to respond favorably to a particular drug or therapy, and those more or less likely to experience unfavorable side effects.(1)The companion diagnostics market, worth an estimated $1.5 billion annually, is reportedly the fastest growing segment in the IVD industry, due largely to demand for safer, higher quality drugs.(2)

Complementing a move into next-generation sequencing, Siemens' companion diagnostics business will establish relationships with pharmaceutical companies to offer clinical trial expertise as well as diagnostic test development and commercialization. The company's CLIA-certified clinical lab in Berkeley, California is capable of offering a broad range of nucleic acids and immunoassay tests, as well as developing new test approaches as required.

"Siemens' presence in the emerging companion diagnostics market enables us to leverage our innovation capabilities and deep clinical knowledge to help improve pharmaceutical drug safety and effectiveness," said Michael Reitermann, CEO, Siemens Healthcare Diagnostics. "More so, it helps align Siemens with new classes of therapies tailored to the individual that hold the promise of improving patient care and delivering on the goal of personalized medicine."

ViiV Healthcare previously announced the start of the Phase III MODERN Study [Maraviroc Once daily with Darunavir Enhanced by Ritonavir in a Novel regimen], also known as A4001095, comparing its CCR5-inhibitor, Celsentri/Selzentry® (maraviroc), to emtricitabine/tenofovir (Truvada®), both in combination with darunavir/ritonavir. The 96-week trial will evaluate a two-drug versus three-drug once-daily regimen for the treatment of antiretroviral-naive patients infected with CCR5-tropic HIV-1.

In addition, MODERN is the first large Phase III trial that will compare the performance of a genotypic test with a phenotypic test in identifying patients appropriate for use of Celsentri/Selzentry®. Patients will be randomised to undergo screening with either the genotypic or phenotypic test. Genotypic tropism testing in the MODERN study is provided by Siemens Healthcare Diagnostics as part of this partnership and phenotypic testing (Trofile®) by Monogram Biosciences. Subject to FDA approval, Siemens Healthcare Diagnostics may commercialize their genotypic tropism diagnostic test.

"Our partnership with Siemens Healthcare Diagnostics is a valuable part of our commitment to addressing patient needs through developing innovative treatment approaches," said Dr. John Pottage, Chief Scientific and Medical Officer, ViiV Healthcare. "Celsentri/Selzentry is an important treatment option for people living with CCR5-tropic HIV and we continue to support the evolution of tropism testing to provide physicians with accurate, accessible and affordable companion diagnostics."

Tocagen is enrolling patients in its clinical trials of Toca 511 (vocimagene amiretrorepvec), for injection & Toca FC (flucytosine), extended-release tablets. These multicenter, open-label studies(3) are in patients with recurrent high-grade glioma, such as those with glioblastoma multiforme (GBM, Grade 4), who have had prior surgery and chemoradiation. Toca 511 is a retroviral replicating vector (RRV) that is designed to deliver a cytosine deaminase (CD) gene selectively to cancer cells. After allowing time for the administered Toca 511 to spread through the tumor, those cancer cells expressing the CD gene may convert the antibiotic flucytosine into the anti-cancer drug 5-fluorouracil (5-FU). In these studies, patients receive multiple cycles of oral Toca FC. Tocagen plans to work with Siemens Healthcare Diagnostics on the assays used during these clinical studies. Subject to FDA approval, Siemens may commercialize diagnostic tests capable of monitoring patient levels of Toca 511 and Toca FC.

"We believe that developing the necessary diagnostic tests with the right diagnostic partner is an important component for the successful commercialization of Toca 511 & Toca FC," said Harry E. Gruber, CEO, Tocagen Inc. "Siemens' capabilities in developing commercial viral assays in addition to their market presence in the diagnostics space make them an excellent complement to Tocagen's focus on the development and commercialization of viral gene transfer products to treat advanced cancer."

These partnerships reflect Siemens' efforts to expand its healthcare global presence by leveraging the power of in vivo and in vitro diagnostics to impact therapeutics – one goal of the recently launched Siemens Agenda 2013, a new two-year global initiative to further strengthen the innovative power and competitiveness of the Siemens Healthcare Sector.

(1) http://www.dddmag.com/article-Companion-Prospecting-91211.aspx (accessed on 10/6/11)
(2) http://www.prnewswire.com/news-releases/companion-diagnostics-world-market-outlook-2011-2021-130615878.html, http://www.visiongain.com (accessed on 10/6/11)
(3) http://clinicaltrials.gov/ct2/results?term=tocagen

ViiV Healthcare is a global specialist HIV company established by GlaxoSmithKline (LSE: GSK.L) and Pfizer (NYSE: PFE) to deliver advances in treatment and care for people living with HIV. Our aim is to take a deeper and broader interest in HIV/AIDS than any company has done before, and take a new approach to deliver effective and new HIV medicines as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline and commitment, please visit: www.viivhealthcare.com.

Tocagen Inc. is a privately funded, clinical stage biopharmaceutical company pursuing the discovery, development and commercialization of gene transfer products for the treatment of cancer. Tocagen is initially focusing on treatments for patients with advanced cancer for whom no adequate treatments currently exist. Toca 511 & Toca FC, the company's lead investigational combination product candidate, is being evaluated in clinical trials in patients with recurrent high grade glioma (such as glioblastoma multiforme). Tocagen has received grant support from leading brain cancer foundations including, Accelerate Brain Cancer Cure (ABC2), the American Brain Tumor Association (ABTA), and the National Brain Tumor Society (NBTS). For more information about Tocagen or Toca 511 please visit: www.tocagen.com.

The Siemens Healthcare Sector is one of the world's largest suppliers to the healthcare industry and a trendsetter in medical imaging, laboratory diagnostics, medical information technology and hearing aids. Siemens offers its customers products and solutions for the entire range of patient care from a single source – from prevention and early detection to diagnosis, and on to treatment and aftercare. By optimizing clinical workflows for the most common diseases, Siemens also makes healthcare faster, better and more cost-effective. Siemens Healthcare employs some 51,000 employees worldwide and operates around the world. In fiscal year 2011 (to September 30), the Sector posted revenue of 12.5 billion euros and profit of around 1.3 billion euros. For further information please visit: www.siemens.com/healthcare.

SOURCE Siemens Healthcare Diagnostics

GSK Upbeat on Solid Results - Interviews with CEO and CFO

Tue, 07 Feb 2012 12:51:00 +0000

GSK Upbeat on Solid Results - Interviews with CEO and CFO

PR Newswire

LONDON, February 7, 2012 /PRNewswire/ --

In an online video interview with MerchantCantos, GlaxoSmithKline CEO Sir Andrew Witty talks about the pharmaceutical group's special dividend, solid results and why the company is so well positioned to continue to deliver.

Sir Andrew said "adversity isn't all downside for everybody" and that the market offered opportunities for companies who had strengthened and had changed their exposure to places of growth.

"This is a time where we should feel optimistic. And certainly at GSK we do feel optimistic. We feel like are moving into a new era for the company and we now need to focus on absolute disciplined execution to make sure that we take advantage of all of the opportunities that we've worked so hard to try and create for ourselves."

CFO Simon Dingemans admitted there had been some margin pressure in Q4 but that he expected margins to improve gradually. "We expect only a very gradual increase in operating margin, and by that I mean a few tens of basis points and more in 2013 and further thereafter."

The interviews and transcripts are available now on http://www.cantos.com/company/GlaxoSmithKline.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@merchantcantos.com or phone +44-207-936-1352.

GSK Upbeat on Solid Results - Interviews with CEO and CFO

Tue, 07 Feb 2012 12:51:00 +0000

GSK Upbeat on Solid Results - Interviews with CEO and CFO

PR Newswire

LONDON, February 7, 2012 /PRNewswire/ --

Sir Andrew said "adversity isn't all downside for everybody" and that the market offered opportunities for companies who had strengthened and had changed their exposure to places of growth.

The interviews and transcripts are available now on http://www.cantos.com/company/GlaxoSmithKline.

SOURCE GlaxoSmithKline

GSK results announcement for Q4 and full year 2011

Tue, 07 Feb 2012 12:10:00 +0000

Issued: Tuesday 07 February 2012, London UK GSK delivers continued underlying sales growth*, R&D progress and improving financial returns to shareholders

2011 underlying sales +4% (reported -3%) EPS before major restructuring* 114.1p Total dividends of 75p

Download GSK Q4 results 2011 as a PDF

Companion Diagnostics Partnering Terms and Agreements

Tue, 07 Feb 2012 10:02:01 +0000

Companion Diagnostics Partnering Terms and Agreements

PR Newswire

NEW YORK, Feb. 7, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Companion Diagnostics Partnering Terms and Agreements

http://www.reportlinker.com/p0362248/Companion-Diagnostics-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Diagnostics

Report description

The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the companion diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter companion diagnostic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors companion diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual companion diagnostics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of companion diagnostic dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in companion diagnostic dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading companion diagnostic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of companion diagnostic deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of companion diagnostic partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in companion diagnostic partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of companion diagnostic technologies and products.

Key benefits

Companion Diagnostics Partnering Terms and Agreements provides the reader with the following Key benefits:

• In-depth understanding of companion diagnostics deal trends since 2007

• Access to headline, upfront, milestone and royalty data

• Analysis of the structure of companion diagnostics agreements with numerous real life case studies

• Comprehensive access to over 1,000 actual companion diagnostics contracts entered into by the world's biopharma companies

• Detailed access to actual companion diagnostics contracts enter into by the leading fifty bigpharma companies

• Insight into the terms included in a companion diagnostics agreement, together with real world clause examples

• Understand the key deal terms companies have agreed in previous deals

• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Companion Diagnostics Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to companion diagnostics trends and structure of deals entered into by leading companies worldwide.

Companion Diagnostics Partnering Terms and Agreements includes:

o Trends in companion diagnostics dealmaking in the biopharma industry since 2007

o Analysis of companion diagnostics deal structure

o Access to headline, upfront, milestone and royalty data

o Case studies of real-life companion diagnostics deals

o Access to over 1,000 companion diagnostics contract documents

o The leading companion diagnostics deals by value since 2007

o Most active companion diagnostics dealmakers since 2007

o The leading companion diagnostics partnering resources

In Companion Diagnostics Partnering Terms and Agreements, the available contracts are listed by:

o Company A-Z

o Headline value

o Stage of development at signing

o Deal component type

o Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Companion Diagnostics Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,000 companion diagnostics deals. Analyzing actual contract agreements allows assessment of the following:

o What are the precise companion diagnostics rights granted or optioned?

o What is actually granted by the agreement to the partner company?

o What exclusivity is granted?

o What is the payment structure for the deal?

o How are sales and payments audited?

o What is the deal term?

o How are the key terms of the agreement defined?

o How are IPRs handled and owned?

o Who is responsible for commercialization?

o Who is responsible for development, supply, and manufacture?

o How is confidentiality and publication managed?

o How are disputes to be resolved?

o Under what conditions can the deal be terminated?

o What happens when there is a change of ownership?

o What sublicensing and subcontracting provisions have been agreed?

o Which boilerplate clauses does the company insist upon?

o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

o Which jurisdiction does the company insist upon for agreement law?

Number of pages:

The report is comprised of 327 pages.Table of contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in companion diagnostic dealmaking

2.1. Introduction

2.2. Companion diagnostics partnering over the years

2.3. Bigpharma companion diagnostic dealmaking activity

2.4. Bigpharma not active in companion diagnostics

2.5. Companion diagnostic partnering by deal type

2.6. Companion diagnostic partnering by disease type

2.7 Average deal terms for companion diagnostics

2.7.1 Companion diagnostic headline values

2.7.2 Companion diagnostic upfront payments

2.7.3 Companion diagnostic milestone payments

2.7.4 Companion diagnostics royalty rates

Chapter 3 – Leading companion diagnostic deals

3.1. Introduction

3.2. Top companion diagnostic deals by value

3.3. Top companion diagnostic deals involving bigpharma

Chapter 4 – Bigpharma companion diagnostic deals

4.1. Introduction

4.2. How to use bigpharma companion diagnostic partnering deals

4.3. Bigpharma companion diagnostic partnering company profiles

Abbott

Abbott Molecular

Actavis

Alcon Labs

Allergan

Amgen

Apotex

Astellas

AstraZeneca

Baxter International

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

Cephalon

CSL

Dainippon Sumitomo

Eisai

Eli Lilly

Forest Laboratories

Genzyme

Gilead Sciences

GlaxoSmithKline

GlaxoSmithKline Biologicals

Hospira

Janssen Biotech

Kyowa Hakko Kirin

Lundbeck

Menarini

Mitsubishi Tanabe

Novartis

Novo Nordisk

Nycomed Pharma

Otsuka

Pfizer

Roche

Roche Diagnostics

Roche Molecular Systems

Genentech

Sanofi

Servier

Shionogi

Stada

Takeda

Teva

Warner Chilcott

Watson

Chapter 5 – Companion diagnostic dealmaking directory

5.1. Introduction

5.2. Company A-Z

5.3. By stage of development

Discovery

Pre-clinical

Phase I

Phase II

Phase III

Registration

Marketed

5.4. By deal type

Asset purchase

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Development

Distribution

Equity purchase

Evaluation

Grant

Licensing

Manufacturing

Marketing

Option

Research

Settlement

Spin out

Sub-license

Supply

Technology transfer

5.5. By therapy area

Cardiovascular

Central nervous system

Dental

Dermatology

Gastrointestinal

Genetic disorders

Genitourinary

Hematology

Hormonal disorders

Hospital care

Immunology

Infection

Inflammatory

Metabolic

Musculoskeletal

Oncology

Ophthalmics

Respiratory

Sensory organ

Chapter 6 – Companion diagnostics partnering resource center

6.1. Online companion diagnostics partnering

6.2. Companion diagnostic partnering events

6.3. Further reading on companion diagnostic dealmaking

Appendices

Appendix 1 – Deal type definitions

Appendix 2 – Example companion diagnostic partnering agreement

About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from CurrentPartnering

Table of figures

Figure 1: Companion diagnostic partnering since 2007

Figure 2: Bigpharma – top 50 – companion diagnostic deals 2007 to 2011

Figure 3: Bigpharma companion diagnostic deal frequency – 2007 to 2011

Figure 4: Inactive bigpharma in companion diagnostic 2007-2011

Figure 5: Companion diagnostic partnering by deal type since 2007

Figure 6: Companion diagnostic partnering by disease type since 2007

Figure 7: Companion diagnostic partnering by oncology target since 2007

Figure 8: Companion diagnostic deals with a headline value

Figure 9: Companion diagnostic deal headline value distribution, US$million

Figure 10: Companion diagnostic deal headline value distribution, US$million

Figure 11: Companion diagnostic deals with upfront payment values

Figure 12: Companion diagnostic deal upfront payment distribution, US$million

Figure 13: Companion diagnostic deals with milestone payments

Figure 14: Companion diagnostic deals with royalty rates, %

Figure 15: Top companion diagnostic deals by value since 2007

Figure 16: Top companion diagnostic deals signed by bigpharma value since 2007

Figure 17: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Cardiovascular)

Figure 18: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Central Nervous System)

Figure 19: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Dermatology)

Figure 20: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Gastrointestinal)

Figure 21: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Hematology)

Figure 22: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Hormonal)

Figure 23: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Hospital care)

Figure 24: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Immunology)

Figure 25: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Infectives)

Figure 26:Recent deals (Jan 2007 to Dec 2011) - By therapy area (Inflammatory)

Figure 27: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Metabolic)

Figure 28: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Musculoskeletal)

Figure 29: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Oncology)

Figure 30: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Ophthalmics)

Figure 31: Online partnering resources

Figure 32: Forthcoming partnering events

Figure 33: Deal type definitions

Figure 34: Companion diagnostic partnering agreement between Roche, Rules-Based Medicine, and Psynova Neurotech, December 2009

To order this report:Diagnostics Industry: Companion Diagnostics Partnering Terms and Agreements

Market Research Report

Check our

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Mon, 06 Feb 2012 09:20:01 +0000

Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

PR Newswire

NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

http://www.reportlinker.com/p0769058/Commercializing-Angiogenesis-Affecting-Drugs-in-Cancer-The-Faster-Route-to-Consider-Your-Options-and-Position-of-Others.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This report will excel your competitive awareness and decrease your decision making time in managing angiogenesis affecting drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

A large number of drugs, both on the market and in development have angiogenesis affecting properties.This report includes both direct angiogenic targets (angiogenesis-related targets) and indirect angiogenic targets (non-angiogenic targets which nevertheless have angiogenesis effects).

This report comprises defined and up to date development strategies for 252 angiogenesis affecting drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the angiogenesis affecting drug pipeline in oncology and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of angiogenesis affecting drugs in cancer is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 44 different clusters. The latter has a competing ratio which is almost two times higher than the comparable average of the angiogenesis affecting drugs in general.

* Eight out of every ten drug target strategies in Phase III development are new to angiogenesis affecting drugs, whereas only five out of every ten target strategies in Phase II are new.

* The greatest number of new target strategies are found in Preclinical (21%) and Phase II (18%) development.

* Small molecules, Antibodies and Proteins drugs are the dominating compound strategies of angiogenesis affecting cancer drugs, which represent almost 80% of the entire pipeline.

* Protein based angiogenesis affecting cancer drugs has the highest cross-over of drug target strategies with other compound strategies, especially with that of Antibodies and Gene therapies.

* Angiogenesis affecting drugs are experiencing targeting competition in five out of every ten cancer indications described, and more so in colorectal cancer, breast cancer and non-small cell lung cancer..

* The highest number of described target strategies among angiogenesis affecting drugs are found in colorectal cancer, breast cancer, non-small cell lung cancer and ovarian cancer.

* The highest number of described drug target strategies of angiogenesis affecting drugs belongs to Pfizer, Novartis, Abbott, Eli Lilly, EntreMed and Exelixis.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any angiogenesis affecting drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.1 Executive Summary 32 About Cancer Highlights™ 52.1 Cancer Focus Areas 52.2 Subscribe Today and Start Saving 62.2.1 Type of License 62.3 Additional Information 62.4 BioSeeker Group's Oncology Team 63 Methodology 73.1 Cancer Highlights'™ Five Pillar Drug Assessment 74 Table of Contents 94.1 List of Figures 224.2 List of Tables225 Introduction 375.1 The Scope of this Report 375.2 Definitions 405.3 Abbreviations 406 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment 416.1 Drug Repositioning in Oncology 416.2 Introduction to Targets of Angiogenesis Affecting Drugs in Oncology 426.2.1 Calcium Ion Binding Targets 486.2.2 Carboxy-lyase Activity Targets 496.2.3 Catalytic Activity Targets 516.2.4 Cell Adhesion Molecule Activity Targets 566.2.5 Chaperone Activity Targets 636.2.6 Chemokine Activity Targets 676.2.7 Cofactor Binding Targets 696.2.8 Cysteine-type Peptidase Activity Targets 716.2.9 Cytokine Activity Targets 766.2.10 Cytoskeletal Protein Binding Targets 806.2.11 DNA Topoisomerase Activity Targets 816.2.12 DNA-directed DNA Polymerase Activity Targets 846.2.13 Extracellular Matrix Structural Constituent Targets 856.2.14 G-protein Coupled Receptor Activity Targets 916.2.15 Growth Factor Activity Targets 966.2.16 GTPase Activity Targets 1126.2.17 Hormone Activity Targets 1156.2.18 Hydrolase Activity Targets 1166.2.19 Kinase Activity Targets 1186.2.20 Kinase Binding Targets 1216.2.21 Lipid Kinase Activity Targets 1236.2.22 Metallopeptidase Activity Targets 1306.2.23 Molecular Function Unknown Targets 1486.2.24 Motor Activity Targets 1496.2.25 Oxidoreductase Activity Targets 1516.2.26 Peptidase Activity Targets 1536.2.27 Phosphoric Diester Hydrolase Activity Targets 1696.2.28 Protease Inhibitor Activity Targets 1726.2.29 Protein Binding Targets 1766.2.30 Protein Serine/Threonine Kinase Activity Targets 1806.2.31 Protein-tyrosine Kinase Activity Targets 2096.2.32 Receptor Activity Targets 2206.2.33 Receptor Binding Targets 2456.2.34 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 2516.2.35 RNA Binding Targets 2536.2.36 Serine-type Peptidase Activity Targets 2546.2.37 Structural Constituent of Cytoskeleton Targets 2596.2.38 Superoxide Dismutase Activity Targets 2616.2.39 Transcription Factor Activity Targets 2646.2.40 Transcription Regulator Activity Targets 2776.2.41 Transferase Activity Targets 2846.2.42 Translation Regulator Activity Targets 2866.2.43 Transmembrane Receptor Activity Targets 2936.2.44 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 2956.2.45 Transporter Activity Targets 3486.2.46 Ubiquitin-specific Protease Activity Targets 3526.2.47 Unknown Function Targets 3536.2.48 Voltage-gated Ion Channel Activity Targets 3546.3 The Cancer Genome Project and Targets of Angiogenesis Affecting Drugs in Oncology 3556.3.1 Targets of Angiogenesis Affecting Drugs in Oncology Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 3556.4 Angiogenesis Affecting Therapeutics is Stimulated by Available Structure Data on Targets 3606.5 Target-Target Interactions among Identified Targets of Angiogenesis Affecting Drugs in Oncology 3646.6 The Drug-Target Competitive Landscape 3686.7 Protein Expression Levels of Identified Targets of Angiogenesis Affecting Drugs in Oncology 3726.8 Pathway Assessment of Angiogenesis Affecting Drugs in Oncology 3756.8.1 Tools for Analysis of Cancer Pathways 3766.8.2 Pathway Assessment 3777 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development 4247.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4267.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4287.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4317.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4387.5 Preclinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 4467.6 Drug Target Strategies of No Data, Suspended or Terminated Angiogenesis Affecting Drugs in Oncology 4507.7 Target Strategy Development Profiles of Angiogenesis Affecting Drugs in Oncology 4547.7.1 Marketed 4587.7.2 Pre-registration 4737.7.3 Phase III 4777.7.4 Phase II 5157.7.5 Phase I 5517.7.6 Preclinical 5827.7.7 Suspended 6187.7.8 Ceased 6197.8 The Competition Through Close Mechanistic Approximation of Angiogenesis Affecting Drugs in Oncology 6608 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy 6678.1 Small Molecules 6698.1.1 Background 6698.1.2 Target Strategies of Small Molecule Drugs 6708.2 Peptide & Protein Drugs 6828.2.1 Background 6828.2.2 Target Strategies of Peptide and Protein Drugs 6838.3 Antibodies 6898.3.1 Background 6898.3.2 Target Strategies of Antibody Drugs 6898.4 Nucleic Acid Therapies 6948.4.1 Background 6948.4.2 Target Strategies of Nucleic Acid Drugs 6958.5 Gene Therapy 6978.5.1 Background 6978.5.2 Target Strategies of Gene Therapy Drugs 6978.6 Drug Delivery and Nanotechnology 7008.6.1 Background 7008.6.2 Target Strategies of Reformulated Drugs 7008.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 7039 Selecting Indication for Angiogenesis Affecting Drugs in Oncology 7109.1 Acute Lymphocytic Leukemia 7139.2 Acute Myelogenous Leukemia 7149.3 Adrenal Cancer 7179.4 B-cell Lymphoma 7189.5 Basal Cell Cancer 7199.6 Biliary Cancer 7209.7 Bladder Cancer 7219.8 Bone Cancer 7249.9 Brain Cancer 7259.10 Breast Cancer 7289.11 Cancer (general) 7349.12 Carcinoid 7359.13 Cervical Cancer 7379.14 Chemopreventative 7389.15 Chronic Lymphocytic Leukemia 7399.16 Chronic Myelogenous Leukemia 7409.17 Chronic Myelomonocytic Leukemia 7419.18 CNS Cancer 7419.19 Colorectal Cancer 7429.20 Endometrial Cancer 7489.21 Fallopian Tube Cancer 7509.22 Fibro Sarcoma 7529.23 Gastrointestinal Cancer (general) 7539.24 Gastrointestinal Stomach Cancer 7569.25 Gastrointestinal Stromal Cancer 7599.26 Head and Neck Cancer 7619.27 Hematological Cancer (general) 7649.28 Hodgkin's Lymphoma 7659.29 Kaposi's Sarcoma 7669.30 Leiomyo Sarcoma 7679.31 Leukemia (general) 7689.32 Lipo Sarcoma 7699.33 Liver Cancer 7709.34 Lung Cancer (general) 7749.35 Lymphangioleiomyomatosis 7769.36 Lymphoma (general) 7779.37 Mast Cell Leukemia 7799.38 Mastocytosis 7799.39 Melanoma 7809.40 Mesothelioma 7849.41 Myelodysplastic Syndrome 7879.42 Myeloma 7899.43 Nasopharyngeal Cancer 7929.44 Neuroendocrine Cancer (general) 7939.45 Neuroendocrine Cancer (pancreatic) 7949.46 Neurofibromatosis 7969.47 non-Hodgkin's Lymphoma 7979.48 Non-Small Cell Lung Cancer 7999.49 Oesophageal Cancer 8059.50 Oral Cancer 8079.51 Osteo Sarcoma 8089.52 Ovarian Cancer 8099.53 Pancreatic Cancer 8139.54 Peritoneal Cancer 8169.55 Prostate Cancer 8189.56 Radio/chemotherapy-induced Alopecia 8229.57 Radio/chemotherapy-induced Infection 8229.58 Renal Cancer 8239.59 Sarcoma (general) 8289.60 Small Cell Lung Cancer 8309.61 Soft Tissue Sarcoma 8339.62 Solid Tumor 8359.63 Squamous Cell Cancer 8399.64 Synovial Sarcoma 8409.65 T-cell Lymphoma 8419.66 Testicular Cancer 8429.67 Thyroid Cancer 8439.68 Unspecified 8459.69 Vaccine adjunct 8489.70 Waldenstrom's hypergammaglobulinemia 84810 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator 84910.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 85310.2 Company Facts and Ranking 85510.3 Competitive Fall-Out Assessment 86110.4 Abbott 86410.5 Acceleron Pharma 87510.6 Access 87910.7 Active Biotech 88310.8 Adherex 88710.9 Advantagene 89510.10 Advaxis 90110.11 Advenchen 90510.12 Aeterna Zentaris 90910.13 Agennix 91610.14 Aida Pharmaceuticals 92010.15 Alnylam 92410.16 Ambit Biosciences 92810.17 Ambrilia Biopharma 93410.18 Amgen 93810.19 Amphora 94610.20 Angiogen 95010.21 Angiogenex 95410.22 Angstrom Pharmaceuticals 95810.23 Ansaris 96210.24 Antisoma 96610.25 Arana Therapeutics 97010.26 Ariad 97410.27 Arno Therapeutics 98410.28 ArQule 98810.29 Array BioPharma 99410.30 Astellas 99810.31 Astex Therapeutics 100410.32 AstraZeneca 100810.33 Attenuon 101610.34 Austrianova 102210.35 Bayer 102610.36 BioAlliance Pharma 103610.37 BioAxone 104110.38 Biocad 104510.39 Boehringer Ingelheim 105110.40 Bolder BioTechnology 105710.41 Bristol-Myers Squibb 106310.42 BTG 107510.43 Cancer Research Technology 108110.44 CDG Therapeutics 108510.45 Celecure 108910.46 Celera 109310.47 Celgene 109710.48 Cell Therapeutics 110510.49 CellCeutix 111010.50 Cellmid 111410.51 Cephalon 111810.52 ChemoCentryx 112210.53 Chemokine Therapeutics 112610.54 China Sky One Medical 113010.55 Choongwae 113410.56 Circadian Technologies 113910.57 Cue Biotech 114410.58 Curis 114810.59 Cyclacel 115410.60 Cytochroma 115810.61 Deciphera Pharmaceuticals 116210.62 Dendreon 116610.63 Dyax 117010.64 Eisai 117410.65 Eli Lilly 118110.66 EntreMed 119510.67 Exelixis 120610.68 ExonHit Therapeutics 121810.69 Five Prime Therapeutics 122210.70 GammaCan 122610.71 Genmab 123310.72 Gilead Sciences 124010.73 GlaxoSmithKline 124710.74 GlycoGenesys 125410.75 Green Cross 125910.76 Hoffmann-La Roche 126410.77 Hy BioPharma 127610.78 Idera Pharmaceuticals 128010.79 ImClone Systems 128710.80 ImmunoGen 129210.81 ImmuPharma 129610.82 Introgen Therapeutics 130010.83 Isis Pharmaceuticals 130510.84 Johnson & Johnson 130910.85 KAI Pharmaceuticals 131710.86 Karus Therapeutics 132210.87 Kirin Pharma 132610.88 Kringle Pharma 133010.89 Kyowa Hakko Kirin 133410.90 Lee's Pharmaceutical 134010.91 Lorus Therapeutics 134410.92 MAT Biopharma 134810.93 MediGene 135210.94 Merck & Co 135810.95 Merck KGaA 136210.96 Mersana Therapeutics 136910.97 MethylGene 137310.98 Micromet 137710.99 MolMed 138110.100 Morvus Technology 138610.101 NewSouth Innovations 139010.102 Non-industrial Source 139410.103 Novartis 139810.104 Novelix 141710.105 Noxxon 142110.106 Oasmia 142510.107 Onconova 142910.108 OncoTherapy Science 143510.109 Oncothyreon 144110.110 OSI Pharmaceuticals 144610.111 Oxford BioMedica 145110.112 OXiGENE 145510.113 Pepscan Therapeutics 146110.114 PepTx 146810.115 Peregrine Pharmaceuticals 147210.116 Pfizer 147910.117 Pharmacopeia 149910.118 PharmaMar 150410.119 Pharminox 151010.120 Philogen 151410.121 PhiloGene 151810.122 Pierre Fabre 152210.123 Progen 152810.124 Protein Sciences 153210.125 Protgen 153710.126 PTC Therapeutics 154210.127 Receptor BioLogix 154910.128 Regeneron 155310.129 Rexahn 156110.130 Rigel 156510.131 Sanofi 156910.132 Santaris Pharma 157610.133 Scancell 158210.134 SciClone Pharmaceuticals 158610.135 Semafore Pharmaceuticals 159010.136 Shionogi 159610.137 Simcere Pharmaceuticals 160010.138 Spear Therapeutics 160810.139 SRI International 161210.140 Stainwei Biotech 161810.141 SuperGen 162210.142 Switch Pharma 162610.143 SynDevRx 163010.144 Taiho 163410.145 Tau Therapeutics 163810.146 ThromboGenics 164210.147 Tigris Pharmaceuticals 164610.148 ToolGen 165010.149 TopoTarget 165710.150 Tracon Pharmaceuticals 166110.151 UCB 166510.152 VBL Therapeutics 167210.153 Wilex 167610.154 Xerion 168211 Disclaimer 168612 Drug Index 168713 Company Index 1697

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology 367Figure 2: The Drug-Target Competitive Landscape of Angiogenesis Affecting Drugs in Oncology - Large Cluster 369Figure 3: The Drug-Target Competitive Landscape Angiogenesis Affecting Drugs in Oncology - Smaller Clusters 370Figure 4: Head-to-Head Targeting Competitive Landscape of Angiogenesis Affecting Drugs in Oncology 371Figure 5: Distribution of Compound Strategies among Angiogenesis Affecting Cancer Drugs 703Figure 6: Primary Sub-cellular Localization of Drug Targets 704Figure 7: Number of Companies per Ranking Level 855

4.2 List of Tables

Table 1: Cancer Highlights'™ Five Pillar Drug Assessment 7Table 2: Breakdown of the Included Angiogenesis Affecting Drug Pipeline in Oncology by Stage of Development 37Table 3: Head to Head Target Competition among Angiogenesis Affecting Drugs in Oncology 37Table 4: Overview of Drug Target Strategy Themes 42Table 5: Terminally Ceased Targets of Angiogenesis Affecting Drugs in Oncology 43Table 6: Official Gene Name to Target Profle 44Table 7: Targets of Angiogenesis Affecting Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 356Table 8: Identity of Drug Targets with Available Biological Structures 360Table 9: Number of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology 365Table 10: Available Protein Expression Profiles of Angiogenesis Affecting Drug Targets in Oncology 372Table 11: Pathway Summary 377Table 12: Drug Targets without any Identified Assigned Pathways 377Table 13: Pathway Profiles According to BioCarta of Angiogenesis Affecting Drug Targets in Oncology 379Table 14: Pathway Profiles According to KEGG of Angiogenesis Affecting Drug Targets in Oncology 397Table 15: Pathway Profiles According to NetPath of Angiogenesis Affecting Drug Targets in Oncology 417Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 424Table 17: Top Competitive Target Strategies of Angiogenesis Affecting Drugs in Oncology 425Table 18: New and Unique Target Strategies of Pre-registration and Marketed Angiogenesis Affecting Drugs in Oncology 426Table 19: The Competition Through Close Mechanistic Approximation Between Angiogenesis Affecting Drugs in Oncology in Pre-registration to Marketed 427Table 20: New and Unique Target Strategies in Phase III Clinical Development of Angiogenesis Affecting Drugs in Oncology 428Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Angiogenesis Affecting Drugs in Oncology 430Table 22: New and Unique Target Strategies in Phase II Clinical Development of Angiogenesis Affecting Drugs in Oncology 431Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Angiogenesis Affecting Drugs in Oncology 435Table 24: New and Unique Target Strategies in Phase I Clinical Development of Angiogenesis Affecting Drugs in Oncology 438Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Angiogenesis Affecting Drugs in Oncology 442Table 26: New and Unique Target Strategies in Preclinical Development of Angiogenesis Affecting Drugs in Oncology 446Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Angiogenesis Affecting Drugs in Oncology 449Table 28: Target Strategies of No Data, Suspended and Terminated Angiogenesis Affecting Drugs in Oncology 450Table 29: Connecting Target Strategy with Its Profile Identification Number 454Table 30: The Competition Through Close Mechanistic Approximation Among Angiogenesis Affecting Drugs in Oncology 660Table 31: Overview of Compound Strategy Competition Among Angiogenesis Affecting Cancer Drugs 668Table 32: Overview of the Competitive Landscape of Small Molecule Based Angiogenesis Affecting Cancer Drugs 670Table 33: Competitive Comparison of Target Strategies of Small Molecule Angiogenesis Affecting Cancer Drugs 671Table 34: Pursued Target Strategies of Small Molecule Drugs Based Angiogenesis Affecting Cancer Drugs 675Table 35: Overview of the Competitive Landscape of Peptide Based Angiogenesis Affecting Cancer Drugs 683Table 36: Competitive Comparison of Target Strategies of Peptide Based Angiogenesis Affecting Cancer Drugs 684Table 37: Pursued Target Strategies of Peptide Based Angiogenesis Affecting Cancer Drugs 684Table 38: Overview of the Competitive Landscape of Protein Based Angiogenesis Affecting Cancer Drugs 686Table 39: Competitive Comparison of Target Strategies of Protein Based Angiogenesis Affecting Cancer Drugs 687Table 40: Pursued Target Strategies of Protein Based Angiogenesis Affecting Cancer Drugs 687Table 41: Overview of the Competitive Landscape of Antibody Based Angiogenesis Affecting Cancer Drugs 689Table 42: Competitive Comparison of Target Strategies of Antibody Based Angiogenesis Affecting Cancer Drugs 690Table 43: Pursued Target Strategies of Antibody Based Angiogenesis Affecting Cancer Drugs 691Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs 695Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs 696Table 46: Pursued Target Strategies of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs 696Table 47: Vectors in Gene Therapy 697Table 48: Overview of the Competitive Landscape of Gene Therapy Based Angiogenesis Affecting Cancer Drugs 697Table 49: Competitive Comparison of Target Strategies of Gene Therapy Based Angiogenesis Affecting Cancer Drugs 698Table 50: Pursued Target Strategies of Gene Therapy Based Angiogenesis Affecting Cancer Drugs 699Table 51:Overview of the Competitive Landscape of Reformulated Angiogenesis Affecting Cancer Drugs 700Table 52: Competitive Comparison of Target Strategies of Reformulated Angiogenesis Affecting Cancer Drugs 701Table 53: Pursued Target Strategies of Reformulated Angiogenesis Affecting Cancer Drugs 702Table 54: Compound Strategies based on Sub-Cellular Localization of Angiogenesis Affecting Cancer Drug Targets 704Table 55 Competitive Summary by Cancer Indication of Angiogenesis Affecting Drugs 711Table 56: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Lymphocytic Leukemia 713Table 57: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Myelogenous Leukemia 714Table 58: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 715Table 59: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Adrenal Cancer 717Table 60: The Competition through Close Mechanistic Approximation between Adrenal Cancer Drugs 717Table 61: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of B-cell Lymphoma 718Table 62: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Basal Cell Cancer 719Table 63: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Biliary Cancer 720Table 64: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bladder Cancer 721Table 65: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 722Table 66: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bone Cancer 724Table 67: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Brain Cancer 725Table 68: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 727Table 69: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Breast Cancer 728Table 70: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 730Table 71: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cancer (general) 734Table 72: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Carcinoid 735Table 73: The Competition through Close Mechanistic Approximation between Carcinoid Drugs 736Table 74: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cervical Cancer 737Table 75: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chemopreventative 738Table 76: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Lymphocytic Leukemia 739Table 77: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelogenous Leukemia 740Table 78: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelomonocytic Leukemia 741Table 79: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of CNS Cancer 741Table 80: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Colorectal Cancer 742Table 81: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 745Table 82: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Endometrial Cancer 748Table 83: The Competition through Close Mechanistic Approximation between Endometrial Cancer Drugs 749Table 84: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fallopian Tube Cancer 750Table 85: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs 751Table 86: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fibro Sarcoma 752Table 87: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Cancer (general) 753Table 88: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 755Table 89: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stomach Cancer 756Table 90: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 757Table 91: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stromal Cancer 759Table 92: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs 760Table 93: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Head and Neck Cancer 761Table 94: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 763Table 95: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hematological Cancer (general) 764Table 96: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hodgkin's Lymphoma 765Table 97: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Kaposi's Sarcoma 766Table 98: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leiomyo Sarcoma 767Table 99: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leukemia (general) 768Table 100: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lipo Sarcoma 769Table 101: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Liver Cancer 770Table 102: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 772Table 103: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lung Cancer (general) 774Table 104: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphangioleiomyomatosis 776Table 105: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphoma (general) 777Table 106: The Competition through Close Mechanistic Approximation between Lymphoma Drugs 778Table 107: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mast Cell Leukemia 779Table 108: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mastocytosis 779Table 109: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Melanoma 780Table 110: The Competition through Close Mechanistic Approximation between Melanoma Drugs 782Table 111: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mesothelioma 784Table 112: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs 786Table 113: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myelodysplastic Syndrome 787Table 114: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myeloma 789Table 115: The Competition through Close Mechanistic Approximation between Myeloma Drugs 790Table 116: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Nasopharyngeal Cancer 792Table 117: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (general) 793Table 118: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (pancreatic) 794Table 119: The Competition through Close Mechanistic Approximation between Neuroendocrine Cancer (pancreatic) Drugs 794Table 120: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neurofibromatosis 796Table 121: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of non-Hodgkin's Lymphoma 797Table 122: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs 798Table 123: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Non-Small Cell Lung Cancer 799Table 124: The Competition through Close Mechanistic Approximation between non-Small Cell Lung Cancer Drugs 802Table 125: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oesophageal Cancer 805Table 126: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 806Table 127: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oral Cancer 807Table 128: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Osteo Sarcoma 808Table 129: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Ovarian Cancer 809Table 130: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 811Table 131: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Pancreatic Cancer 813Table 132: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 815Table 133: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Peritoneal Cancer 816Table 134: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 817Table 135: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Prostate Cancer 818Table 136: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 820Table 137: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Radio/chemotherapy-induced Alopecia 822Table 138: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Radio/chemotherapy-induced Infection 822Table 139: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Renal Cancer 823Table 140: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 826Table 141: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Sarcoma (general) 828Table 142: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs 829Table 143: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Small Cell Lung Cancer 830Table 144: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 831Table 145: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Soft Tissue Sarcoma 833Table 146: The Competition through Close Mechanistic Approximation between Soft Tissue Sarcoma Drugs 834Table 147: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Solid Tumor 835Table 148: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 837Table 149: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Squamous Cell Cancer 839Table 150: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Synovial Sarcoma 840Table 151: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of T-cell Lymphoma 841Table 152: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Testicular Cancer 842Table 153: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Thyroid Cancer 843Table 154: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Unspecified 845Table 155: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Vaccine adjunct 848Table 156: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Waldenstrom's hypergammaglobulinemia 848Table 157: Competitive Summary by Investigator of Angiogenesis Affecting Drug Development 849Table 158: Summary Table of Corporate Changes in the Competitive Landscape of Angiogenesis Affecting Drug Development in Oncology 853Table 159: Example of a Competitive Fall-Out Table (Targeting KDR/Modified) 861Table 160: Abbott's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 867Table 161: Acceleron Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 876Table 162: Access'Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 880Table 163: Active Biotech's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 884Table 164: Adherex's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 889Table 165: Advantagene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 896Table 166: Advaxis'Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 902Table 167: Advenchen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 906Table 168: Aeterna Zentaris'Include

To order this report:Pathology Industry: Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

More Market Research Report

Check our Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

Mon, 06 Feb 2012 09:07:24 +0000

World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

PR Newswire

NEW YORK, Feb. 6, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

http://www.reportlinker.com/p0769020/World-Market-for-Anti-Infectives-Antifungals-Antibacterials-and-Antivirals- .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

This Kalorama Information report – The World Market for Anti-Infectives - focuses on three key segments of treatment:

Antifungals (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

Antibacterials (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)

Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals)

The report covers both currently marketed and late stage development products. Revenues for each segment were generated using dollar and unit sales for each product.

A novel approach of this report is it provides revenue

by product type

but also the 'market' for treatments

by type of infection

, enabling the marketer to research the best markets where a variety of products may be implemented.

The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers.

The area of anti-infectives represents an exciting frontier for development of potential life-saving products. However, there are a number of issues and trends that have a direct influence on this market and the manufacturer's ability to successfully operate in the market. The issues and trends affecting this market include:

Drug Resistance

HIV Trends, Cost, and Access to Drug Therapy

Other Immunocompromised Population Issues

Alliances and Partnerships

New Developments

Rx-to-OTC Switches

CHAPTER ONE: EXECUTIVE SUMMARY

Introduction

Scope and Methodology

Total Size and Growth of the Market

Issues and Trends Affecting Market

Leading Competitors

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

Overview

Introduction to Pathogens

Demographics of the World

Life Expectancy

Infections and Drug Resistance

Causes of Drug Resistance

Drug Resistance in Select Populations

Measures for Reducing Resistance

HIV Trends

Manufacturer and Marketer Trends

Trends in Partnerships and Alliances

Developers Trends

Aradigm

ARD-3100

Phase II

Cystic fibrosis

ARD-3150

Phase II

Bronchiectasis

ARD-1100

Preclinical

Inhalation anthrax

Trends in Rx-to-OTC Switches

CHAPTER THREE: ANTIFUNGAL DRUGS

Overview

Types of Fungal Infections

Superficial

Systemic

General Fungal Infection Statistics

Fungal Infection Risk

Description of Antifungal Products

Systemic Antifungals

Topical Antifungals

Market Overview

Total Market Size and Forecast

Antifungal Market by Product Type

Antifungal Market by Geographical Region

Market Analysis by Treated Condition

Competitive Analysis

Leading Products

CHAPTER FOUR: ANTIBACTERIAL DRUGS

Overview

Classification of Antibacterial Organisms

Antimicrobial Spectrum

Bacterial Resistance

Principles of Anti-bacterial Therapy

Combination Therapy and Prophylactic Use

Bacterial Infection Statistics

Bacterial Infection Risk

Classifications of Antibacterial Products

Aminoglycosides

Carbapenems

Cephalosporins

Macrolides

Penicillins

Quinolones

Sulfonamides

Tetracyclines

Market Overview

Total Market Size and Forecast

Antibacterial Market by Product Type

Antibacterial Market by Geographical Region

Market Analysis by Treated Condition

Competitive Analysis

Leading Products

CHAPTER FIVE: ANTIVIRAL DRUGS

Overview: Introduction to Viruses

Examples of Pathogenic Viruses

Virus Function and Life History

Replication in DNA Viruses

Replication of RNA Viruses

Replication in Retroviruses

Host Defenses Against Viruses 8

Viral Ploys to Invade Host Cells and Circumvent Host Responses

Invasion of Host Cells

Subversion of the Immune Response

Avoidance of Immune Detection and Attack by Killer Cells

HIV and AIDS

Viral Infection Statistics

Description of Antivirals Products

Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors

Protease Inhibitors

Other Antivirals

Market Overview

Total Market Size and Forecast

Antiviral Market by Product Type

Antiviral Market by Geographical Region

Market Analysis by Treated Condition

Competitive Analysis

Leading Products

CHAPTER SIX: MARKET SUMMARY

Market by Product Segment (Antifungals, Antibacterials, Antivirals)

CHAPTER SEVEN: CORPORATE PROFILES

Introduction

Abbott Laboratories

Astellas

AstraZeneca

Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma)

Bristol-Myers Squibb

Cubist

Daiichi Sankyo

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Merck

Novartis

Pfizer

Roche

APPENDIX: COMPANY DIRECTORY

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: The Global Market for Anti-Infectives by Product Segment, 2007-2015

Figure 1-1: The Global Market for Anti-Infectives by Product Segment, 2011

Figure 1-2: World Market for Anti-Infectives Estimated Market Share of Leading Suppliers, 2011

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

Table 2-1: World Population by Selected Geographical Region, 2010 - 2050

Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2009

Figure 2-2: Average Life Expectancy in Years by Country 1980 and 2009

Table 2-3: Worldwide HIV/AIDS Infections

Table 2-4: Women Living with HIV/AIDS, by Region 2001 to 2009, Number

Table 2-5: Antiretroviral Access for HIV Infected Individuals in Low- and Middle-Income Countries, 2009 based on 2010 WHO Guidelines

Table 2-6: Antiretroviral Access for HIV Infected Individuals in Low- and Middle-Income Countries, by Selected Countries, 2009 based on 2010 WHO Guidelines

Table 2-7: Anti-Infective Drugs in Development by Developer

Table 2-8: Anti-infectives Ingredients Transferred from Rx-to-OTC Status

Figure 2-3: Anti-infectives Ingredients Transferred from Rx-to-OTC by Year

CHAPTER THREE: ANTIFUNGAL DRUGS

Table 3-1: Incidence of Infections by Type, 2010

Figure 3-1: Incidence of Infections by Type, 2010

Table 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

Figure 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

Table 3-3: Treatment Options for Fungal Infections , (Type, Brand, and Manufacturer)

Table 3-4: The World Market for Antifungal Drugs 2007-2015

Figure 3-3: The World Market for Antifungal Drugs 2007-2015

Table 3-5: Antifungal Drug Market by Type 2007-2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

Figure 3-4: The World Market for Antifungal Drugs Revenues by Type 2007-2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

Figure 3-5: The World Market for Antifungal Drugs Revenues by Type 2011 and 2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

Table 3-6: The World Market for Antifungal Drugs Estimated Products Sales by Geographic Region 2007-2015

Figure 3-6: The World Market for Antifungal Drugs Estimated Product Sales by Geographic Region 2007-2015

Table 3-7: World Antifungal Market Estimated Products Sales by Infection Type , (Candida Infections, Seborrheic Dermatitis, Onychomycosis, Other Infections)

Figure 3-7: World Antifungal Market Estimated Distribution of Products Sales by Infection Type, 2011 Candida Infections, Seborrheic Dermatitis, Onychomycosis, Other Infections)

Table 3-8: World Market for Antifungal Drugs Estimated Revenues and Market Share of Leading Suppliers 2007-2011

Figure 3-8: World Market for Antifungal Drugs Estimated Revenues of Leading Suppliers, 5-year Comparison 2007-2011

Figure 3-9: World Market for Antifungal Drugs Estimated Market Share of Leading Suppliers, 2011

Table 3-9: World Market for Antifungal Drugs Estimated Sales of Select Products 2007-2011

Figure 3-10: World Market for Antifungal Drugs Estimated Sales of Select Products 2007-2011

CHAPTER FOUR: ANTIBACTERIAL DRUGS

Table 4-1: Antibiotics with Difficult Penetration

Table 4-2: Estimated World and U.S. Incidence of Bacterial Infections, 2010

Figure 4-1: Estimated World and U.S. Incidence of Bacterial Infections

Table 4-3: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

Figure 4-2: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

Table 4-4: Treatment Options for Bacterial Infections , (Type, Brand, and Manufacturer)

Table 4-5: The World Market for Antibacterial Drugs 2007-2015

Figure 4-3: The World Market for Antibacterial Drugs 2007-2015

Table 4-6: Antibacterial Drug Market by Type 2007-2015

Figure 4-4: The World Market for Antibacterial Drugs Revenues by Type, 2007-2015 , (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)

Figure 4-5: The World Market for Antibacterial Drugs Revenues by Type 2011 and 2015 , (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)

Table 4-7: The World Market for Antibacterial Drugs Estimated Products Sales by Geographic Region 2007-2015

Figure 4-6: The World Market for Antibacterial Drugs Estimated Product Sales by Geographic Region 2007-2015

Table 4-8: World Antibacterial Market Estimated Products Sales by Infection Type , (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections)

Figure 4-7: World Antibacterial Market Estimated Distribution of Products Sales by Infection Type, 2011 , (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections)

Table 4-9: World Market for Antibacterial Drugs Estimated Revenues and Market Share of Leading Suppliers 2007-2011

Figure 4-8: World Market for Antibacterial Drugs Estimated Revenues of Leading Suppliers 2007-2011

Figure 4-9: World Market for Antibacterial Drugs Estimated Market Share of Leading Suppliers, 2011

Table 4-10: World Market for Antibacterial Drugs Estimated Sales of Select Products 2007-2011

CHAPTER FIVE: ANTIVIRAL DRUGS

Table 5-1: Host Cell Receptors

Table 5-2: Estimated World and U.S. Incidence of Viral Infections, 2010

Figure 5-1: Estimated World and U.S. Incidence of Leading Viral Infections

Table 5-3: Treatment Options for Viral Infections , (Type, Brand, and Manufacturer)

Table 5-4: The World Market for Antiviral Drugs 2007-2015

Figure 5-2: The World Market for Antiviral Drugs 2007-2015

Table 5-5: Antiviral Drug Market by Type 2007-2015

Figure 5-3: The World Market for Antiviral Drugs Revenues by Type , (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) 2007-2015

Figure 5-4: The World Market for Antiviral Drugs Revenues by Type , (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) 2011 and 2015

Table 5-6: The World Market for Antiviral Drugs Estimated Products Sales by Geographic Region 2007-2015

Figure 5-5: The World Market for Antiviral Drugs Estimated Product Sales by Geographic Region 2007-2015

Table 5-7: World Antiviral Market Estimated Products Sales by Infection Type (HIV, Hepatitis, Other Infections, Total)

Figure 5-6: World Antiviral Market Estimated Distribution of Products Sales by Infection Type, 2011 (HIV, Hepatitis, Other Infections, Total)

Table 5-8: World Market for Antiviral Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009

Figure 5-7: World Market for Antiviral Drugs Estimated Revenues of Leading Suppliers 2007-2011

Figure 5-8: World Market for Antiviral Drugs Estimated Market Share of Leading Suppliers, 2011

Table 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2007-2011

Figure 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2007-2011

CHAPTER SIX: MARKET SUMMARY

Table 6-1: The Global Market for Anti-Infectives by Product Segment, 2007-2015

Figure 6-1: The World Market for Anti-Infective Drugs 2007-2015

Figure 6-2: The Global Market for Anti-Infectives by Product Segment, 2011

Figure 6-3: The Global Market for Anti-Infectives by Product Segment, 2015

To order this report:Drug and Medication Industry: World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

Market Research Report

Check our

Industry Analysis and Insights

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Medicago Announces Investment in Quebec City Pilot Production Facility

Fri, 03 Feb 2012 12:00:00 +0000

Medicago Announces Investment in Quebec City Pilot Production Facility

PR Newswire

QUEBEC CITY, Feb. 3, 2012 /PRNewswire/ - Medicago Inc. (TSX : MDG), a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced it plans to invest approximately $4 million to enhance the capacity of the pilot production facility located in Quebec City. The Company expects this investment to accelerate preclinical and clinical development timelines of future product candidates. This new investment includes capital expenditures and labour costs, as well as preclinical studies for a rabies vaccine and other products.

"Investing in our Quebec City facility is an important step for Medicago as we look towards expanding our product candidate pipeline," said Andrew Sheldon, President and CEO of Medicago. "We are happy to invest in our local community with the addition of approximately 20 new employees in 2012."

"We would like to thank CQDM for their past support of the VLPExpress™ platform, which has allowed us to accelerate our discovery and development of new vaccines," said Louis-Philippe Vezina, Chief Scientific Officer of Medicago. "The VLPExpress™ platform is now a key component in the development of our new products."

In 2009, Medicago was awarded $1.77 million in funding by the Quebec Consortium for Drug Discovery (CQDM) to support the development of VLPExpress™, an automated high-throughput platform enabling the rapid expression, purification and testing of VLPs to identify the best antigen presentations for a disease-causing agent within ten weeks.

"Medicago was one of the recipients of the first CQDM competition. Our financial support and unique collective approach allowed Medicago to strengthen its leadership position and increase its capacity to develop new products," said Max Fehlmann, President and CEO of CQDM. "We are very proud to be a part of Medicago's remarkable success. This reinforces the role of CQDM in promoting innovation and creating economic value for the research community in Quebec."

About Medicago
Medicago is a clinical-stage biopharmaceutical company developing novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The Company is committed to providing highly effective and competitive vaccines and therapeutic proteins based on its proprietary VLP and manufacturing technologies. Medicago is a worldwide leader in the development of VLP vaccines using a transient expression system which produces recombinant vaccine antigens in plants. This technology has potential to offer more potent vaccines with speed and cost advantages over competitive technologies, enabling the development of a vaccine for testing in approximately one month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic, and supply large volumes of vaccine antigens to the world market. Medicago also intends to expand development into other areas such as biosimilars and biodefense products where the benefits of our technologies can make a significant difference. Additional information about Medicago is available at www.medicago.com.

About the CQDM
The Québec Consortium for Drug Discovery (CQDM) is a meeting ground for all stakeholders in biopharmaceutical research. Its principal mission is to fund research projects carried out in partnership between the academic and hospital milieus in the public sector and the pharmaceutical and biotechnology industries in the private sector. An innovative Canadian initiative, the CQDM has a twofold goal: to accelerate the drug discovery process and to develop safer and more effective drugs. Project funding is made possible through contributions from the Ministère du Développement Économique, de l'Innovation et de l'Exportation (MDEIE) du Québec, the Fonds de recherche Québec - Santé (FRQ-S), the Business-Led Networks of Centres of Excellence (BL-NCE), Pfizer Canada, AstraZeneca, Merck, Boehringer Ingelheim (Canada) Ltd., GlaxoSmithKline and Eli Lilly Canada Inc. For more information: www.cqdm.org.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with Medicago's business and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions to the extent they relate to Medicago or its management. The forward-looking statements are not historical facts, but reflect Medicago's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations, including the matters discussed under "Risks Factors and Uncertainties" in Medicago's Annual Information Form filed on March 31, 2011 with the regulatory authorities. Medicago assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

SOURCE Medicago Inc.

Ronnie Andrews Joins Life Technologies as President, Medical Sciences

Thu, 02 Feb 2012 13:00:00 +0000

Ronnie Andrews Joins Life Technologies as President, Medical Sciences

Leveraging 25-Plus Years Diagnostic Industry Experience, Andrews Will Shape Life Technologies Molecular Diagnostics Business

PR Newswire

CARLSBAD, Calif., Feb. 2, 2012 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced that Ronnie Andrews, former CEO of Clarient and Segment Leader, GE Molecular Diagnostics, has joined the company as President, Medical Sciences. Andrews has more than 25 years of experience in the diagnostics industry, including leadership positions at companies such as Abbott Diagnostics and Roche Diagnostics.

As President, Medical Sciences at Life Technologies, Andrews will apply his expertise to expand Life's presence in the diagnostics and personalized medicine space through strategies including short and long term partnerships.

"Ronnie is one of the most dynamic and respected leaders in the diagnostic industry," said Gregory T. Lucier, Life Technologies' Chairman and Chief Executive Officer. "He adds to Life's management team a deep expertise in commercializing diagnostics, particularly in the molecular domain."

Andrews' accomplishments in diagnostics include:

GE Healthcare – As CEO Clarient and Segment Leader, GE Molecular Diagnostics, Andrews led integration of Clarient, maintaining 20 per cent annual growth and establishing a strategic plan to expand GE's presence in oncology diagnostics.
Clarient – As CEO, Andrews transformed former ChromaVision into a comprehensive cancer diagnostics company, leading the organization from $6MM in annual revenue to $120MM. He raised more than $50MM in capital to fund growth, obtained exclusive licenses for oncology biomarkers and successfully launched new molecular tests for cancers, including leukemia and melanoma. GE Healthcare purchased Clarient in December of 2010 for $587MM, a 5.8-fold multiple of sales.
Roche Molecular Diagnostics – As Senior Vice President, Global Marketing and Commercial Business Operations, Andrews directed annual growth rates of 20 per cent and was instrumental in building Roche's HIV molecular testing business, establishing molecular as the gold standard for infectious disease testing.

"Life has multiple platforms that can be leveraged in the diagnostics market in the near term," said Andrews. "It was the disruptive Ion Torrent technology, however, that tipped the scale for me to come on board."

Ion Torrent semiconductor sequencers offer unprecedented speed, scalability and simplicity. In 2012, the company plans to submit the Ion Personal Genome Machine™ for FDA clearance. Life also recently unveiled the Ion Proton™ Sequencer, which will sequence an entire human genome in several hours on a bench top for $1,000, a development expected to significantly accelerate personalized medicine.

In October 2011, Life announced an agreement with GlaxoSmithKline to develop a companion diagnostic for a GSK candidate cancer therapy, and the company's 7500 Fast Dx Real-Time PCR Instrument is FDA-cleared for use with the U.S. Centers for Disease Control and Prevention (CDC) H1N1 assay.

"I have a long-term and deep commitment to the principles of personalized medicine," said Andrews, "as well as a personal dedication to utilizing emerging molecular knowledge to advance our ability to manage complex diseases like cancer. I look forward to the opportunity to help build Life Technologies into a leader in the diagnostics space."

Andrews received his B.S. in Biology and Chemistry from Wofford College. He began his career with Abbott Diagnostics and also served as vice president of marketing for Immucor Inc.

About Life Technologies
Life Technologies Corporation is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan® products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 4,000 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo: http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact :
Suzanne Clancy
760-602-4545
760-717-8294 (mobile)
suzanne.clancy@lifetech.com

SOURCE Life Technologies Corporation

World's Leading Pharmaceutical Executives All Converging in Zurich, Switzerland on February 21-22, 2012 for Breakthrough Event

Wed, 01 Feb 2012 14:00:00 +0000

World's Leading Pharmaceutical Executives All Converging in Zurich, Switzerland on February 21-22, 2012 for Breakthrough Event

PR Newswire

ZURICH, Feb. 1, 2012 /PRNewswire/ -- The buzz is growing stronger and stronger for one of the most talked-about events in 2012- the Pharma CI Europe Conference on February 21-22, 2012 at the Renaissance Zurich Hotel in Switzerland (http://pharmaciconference.com/ ). "With more than 150 top pharmaceutical executives already attending, people are already saying that this event is sure to make waves among the industry's influential decision makers," says conference organizer Amy Yueh. "After all, this event is the counterpart to our annual Pharma CI USA Conference, scheduled for September 11-12 in Parsippany, New Jersey, which is the largest gathering of biopharma competitive intelligence execs in the world with over 300 CI professionals attending annually."

Conference participants will benefit from the impressive speaking faculty of more than 40 expert speakers from prestigious companies like Actelion, Amgen, Bausch + Lomb, Chiesi Farmaceutici, DSM, F. Hoffmann-La Roche, GlaxoSmithKline, Helsinn Healthcare, Johnson & Johnson, MedImmune, Merck, Norbrook, Novartis, Nycomed, Onyx, Pfizer, Sanofi-Aventis, Shire, Takeda, Virbac, and many more!

These senior level speakers are prepared to delve deep into meaningful discussions about the latest and most pressing issues. To see the detailed program agenda, go to: http://www.pharmaciconference.com/EUR_program.html

The Pharmaceutical Competitive Intelligence Europe Conference provides the ideal atmosphere for learning and debating the industry's most pressing topics. This is the only event that brings together all the industry's decision makers and experts in an atmosphere that promotes gaining insight, developing and solidifying meaningful working relationships, and providing clear directives about the future of this important industry.

The 2012 Pharma CI Europe Conference sponsors/exhibitors include the following: Deallus Group; Lifescience Dynamics; Citeline; Pennside; Adis; BioMedTracker; Digimind; Evaluate Pharma; Evalueservce; Financial Times; Fletcher/CSI; Fuld & Company; ISIS; Larvol; PharmaVoxx; Prescient; SAI MedPartners; Sedulo Group; Value Edge.

The Pharma CI Conference is THE INDUSTRY'S GOLD STANDARD for senior level pharmaceutical, biotechnology, medical device, and diagnostics professionals seeking the latest news and the industry's best networking opportunities. More than 300 people attended the 2011 event in the U.S., and now it's Europe's turn!

For more information, go to http://pharmaciconference.com/ , call +1-212-228.7974, or email info@pharmaciconference.com

Contact:
Amy Yueh
Pharma CI Conference
+ 1 212 228 7974
www.pharmaciconference.com

SOURCE Pharma CI Conference

Alzheimer Disease - New Drugs, Markets and Companies

Wed, 01 Feb 2012 10:22:18 +0000

Alzheimer Disease - New Drugs, Markets and Companies

PR Newswire

NEW YORK, Feb. 1, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Alzheimer disease - New drugs, markets and companies

http://www.reportlinker.com/p0203533/Alzheimer-disease---New-drugs-markets-and-companies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Alzheimer's disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechanism of the disease and find a cure. The only drugs approved currently are acetylcholinesterase inhibitors but they do not correct the basic pathology of the disease, beta amyloid deposits and neurofibrillary tangles. Several new approaches emphasize neuroprotection as well.

Early diagnosis of Alzheimer's disease is an important first step in management. Several biomarkers in cerebrospinal fluid, blood and urine can detect the disease. They provide a valuable aid to the clinical examination and neuropsychological testing which are the main diagnostic methods supplemented by brain imaging. Genotyping, particularly of ApoE gene alleles is also useful in the evaluation of cases and planning management.

The current management of Alzheimer's disease is reviewed and it involves a multidisciplinary approach. Acetylcholinesterase inhibitors are mostly a symptomatic treatment but some claims are made about a neuroprotective effect. Currently the only approved neuroprotective therapy in is memantine. Management of these patients also require neuroleptics for aggressive behavior and antidepressants. There is an emphasis on early detection at the stage of mild cognitive impairment and early institution of neuroprotective measures. The value of mental exercise in delaying the onset of Alzheimer's disease is being recognized.

Research in Alzheimer's disease still aims at elucidating the basic pathomechanisms. Animal models are important for research, particularly in testing some of the potential therapeutic approaches. There is considerable research in progress at the various centers, some of which is funded by the National Institute of Aging of the National Institutes of Health.

Over 300 different compounds are at various stages of development for the treatment of Alzheimer's disease. These are classified and described. There are non-pharmacological approaches such as vagal nerve stimulation and cerebrospinal fluid shunting, which are in clinical trials. Approximately 180 clinical trials are listed, of which 126 are still in progress and 54 were discontinued for various reasons.

Alzheimer's disease market in the seven major markets is analyzed for the year 2011. Several new therapies are expected to be in the market and the shares of various types of approaches are estimated for the future up to the year 2021. As a background to the markets, pharmacoeconomic aspects of care of Alzheimer disease patients and patterns of practice are reviewed in the seven major markets.

Profiles of 140 companies involved in developing diagnostics and therapeutics for Alzheimer's disease are presented along with 110 collaborations. The bibliography contains over 850 publications that are cited in the report.The report is supplemented with 44 tables and 15 figures.

TABLE OF CONTENTS

0. Executive Summary 19

1. Clinical Features, Epidemiology and Pathology 21

Introduction 21

Historical aspects 21

Clinical features of Alzheimer disease 22

Seven stages of Alzheimer disease 24

AD as a terminal illness 26

Detection of AD in the preclinical phase 26

Differentiation of AD from other dementias 26

Differentiation of AD from non-dementing disorders 27

Cerebral insufficiency and AD 28

Memory deficits and preclinical AD 28

Mild cognitive impairment 29

Evolution of diagnostic criteria of AD 31

Revised criteria for the clinical diagnosis of AD 32

Epidemiology 33

Epidemiology of aging 33

Epidemiology of dementia 35

Epidemiology of AD 35

Prevalence of AD according to age 36

Mortality in AD 36

Pathophysiology of AD 37

Cerebral atrophy and neuronal loss 37

Neuritic plaques and neurofibrillary tangles 37

Sp proteins as markers of neuronal death in AD 38

Role of tau in the pathogenesis of AD 38

Amyloid precursor protein 39

Relation of APP mutations to CNS disorders 40

Relation of APP to A? deposits and pathogenesis of AD 40

APP intracellular domain 42

Role of secretases in amyloid cascade 42

Role of exosomal proteins 44

Role of nicastrin 44

Neurotixicity of A? deposits 44

Relation of A? deposits to synaptic activity 45

Dysfunction of TGF-? signaling accelerates A? deposition 45

Role of TMP21 in presenilin complexes and A? formation 45

Role of A? dimers in the pathogenesis of AD 46

Structure–neurotoxicity relationships of A? oligomers 46

A? deposit and clearance 46

Impairment of mitochondrial energy metabolism 47

A?-binding alcohol dehydrogenase links AD to mitochondrial toxicity 48

Neural thread protein 48

Loss of synaptic proteins 48

AD and Down syndrome 49

Overlapping pathologies of AD and Parkinson disease 49

AD and age-related macular degeneration 50

Myelin hypothesis of AD 50

Blood-brain barrier in AD 50

Blood vessel damage in AD 52

Loss of serotonin 1A receptors in the brain 52

Factors in pathogenesis of AD 52

Aerobic glycolysis and AD 52

Astrocytes and AD 52

Axonal transport failure in AD 53

Cell-cycle hypothesis 53

Chronic heart failure link with AD 54

Creatine and AD 54

Disturbances of interaction of nervous system proteins 54

DENN/MADD expression and enhanced pro-apoptotic signaling in AD 54

Gonadotrophins and AD 55

Glutamate transport dysfunction in AD 55

Innate immune system and AD 56

Insulin, diabetes and AD 57

Mechanisms underlying cognitive deficits in AD 57

Monoamine oxidase and AD 58

Neuroinflammation and AD 58

Neurotransmitter deficits 59

Neurotrophic factors 60

NF-?B signaling and the pathogenesis of neurodegeneration 60

Nitric oxide and AD 61

Nogo receptor pathway 63

Oxidative stress and AD 63

Prostaglandins and AD 65

Quinolinic acid and AD 65

Retromer deficiency 65

Serotonin and AD 66

Spherotoxin 66

Synaptic failure in AD 66

Transmission of AD 67

Ubiquitin-proteasome system in pathogenesis of AD 67

Risk factors in the etiology of AD 68

Aging and developmental abnormalities of the cholinergic system 69

Cholesterol, dietary lipids, and A? 69

Exposure to magnetic fields 70

Family history of AD 70

Homocysteine and AD 70

Level of education/type of job and risk of AD 71

Metals and AD 72

Obesity 73

Proneness to psychological distress and risk of AD 74

Reduced muscle strength 74

Sleep deprivation 74

Traumatic brain injury and AD 75

Vascular risk factors for AD 76

Vitamin B12 and folate 77

AD versus non-dementing changes in the aging brain 77

AD and cognitive impairment with aging 78

Pathomechanism of memory impairment and AD 78

Concluding remarks on pathophysiology of AD 79

Genetics of AD 80

Familial AD 80

Presenilins and calcium channel leak in pathogenesis of familial AD 82

Late onset AD 82

Genomics of AD 82

Introduction to genomics 82

Genes associated with Alzheimer disease 83

AlzGene database 84

ApoE gene 84

ApoE genotype and nitric oxide 85

ApoE genotype modulates AD phenotype 86

APOE genotype and age-related myelin breakdown 86

ApoE receptor interaction with NMDA receptor 87

ApoE and ApoER2 87

ApoE receptor LR11 as regulator of A? 88

Arctic mutation 88

CALHM1 polymorphism and AD 88

CLU, CRI and PICALM 88

CYP46 and risk for AD 89

DAPK1 gene variants and AD 89

Genetic variants associated with late-onset AD 89

Copy number variation (CNV) in LOAD 90

LRRTM3 as a candidate gene for AD 90

MTHFD1L gene variant associated with AD 90

OGG1 mutations associated with AD 91

SORL1 gene in AD 91

TOMM40 gene and risk of AD 91

International Genomics of Alzheimer's Project 91

Molecular neuropathology 92

Role of microRNAs in AD 92

AD as a polygenic disorder 93

Proteomics of AD 93

Introduction 93

Application of proteomic technologies to study AD 93

Protein misfolding in AD 95

Common denominators of AD and prion diseases 96

Amyloid fibrils as a common feature of AD and prion diseases 97

FE65 proteins and AD 97

2. Diagnostic Procedures for Alzheimer Disease 99

Importance of the diagnosis of Alzheimer disease 99

Methods of diagnosis of AD 99

Self-administered olfactory test 100

Neuropsychological testing 100

Assessment and evaluation 101

7-minute screen 101

15-point risk index 102

Measurement of aggregation in anterior segment of the eye 102

Activities of Daily Living 102

Alzheimer Disease Cooperative Study 103

CDR-SOB score 103

Clinician's Interview-Based Impression of Change 103

Resource Utilization in Dementia Battery 103

DETECT? System 103

Electrophysiology 104

EEG-based bispectral index 104

Event-related potentials 104

Correlation of electrical activity of the brain with cognition 104

Early detection of cataract associated with AD 105

Retinal imaging to detect A? deposits 105

Laboratory methods for diagnosis of AD 105

Monitoring of synthesis and clearance rates of A? in the CSF 105

Molecular diagnostics for AD 106

Genetic tests for AD 107

ApoE genotyping 107

Gene expression patterns in AD 108

Molecular fingerprinting of the immune system in AD 108

Microarray-based tests for AD 108

Monoclonal antibody-based in vitro diagnosis of AD from brain tissues 109

Biomarkers of AD 109

The ideal biomarker for AD 111

CSF biomarkers of AD 111

CSF sulfatide as a biomarker for AD 111

Glycerophosphocholine as CSF biomarker in AD 112

Protein biomarkers of AD in CSF 112

Amyloid precursor protein 114

Tau proteins in CSF 114

Tests for the detection of A? in CSF 114

Tests combining CSF tau and A? 115

Urine tests for AD 115

Blood tests for AD 116

Blood A? levels 116

Blood test for AD based on heme oxygenase-1 117

Blood test for AD based on RNA hybridization 117

GSK-3 elevation in white blood cells 117

Lymphocyte Proliferation Test 118

Protein kinase C in red blood cells 118

Sphingolipids 118

Tests based on protein biomarkers in blood 118

A skin test for early detection of AD 119

Saliva-based tests for AD 119

Saliva A?42 level as a biomarker of AD 119

Nanotechnology to measure A?-derived diffusible ligands 120

Simultaneous measurement of several biomarkers for AD 120

Plasma biomarkers of drug response in AD 121

A serum protein-based algorithm for the detection of AD 121

Concluding remarks about biomarkers for AD 121

Imaging in AD 122

Computed tomography 122

Magnetic resonance imaging 122

Arterial spin labeling with MRI 123

Magnetic resonance microscopy 123

Magnetic resonance spectroscopy 123

Single photon emission computed tomography and modifications 124

Positron emission tomography 125

In vivo imaging of A? deposits by PET 126

Pittsburgh compound B and PET 127

Florbetapir-PET 128

Florbetaben-PET 128

In vivo detection of A? plaques by MRI 129

Imaging agents for A? and neurofibrillary tangles 129

Targeting of a chemokine receptor as biomarker for brain imaging 130

Radioiodinated clioquinol as a biomarker for A? 130

Imaging neuroinflammation in AD 130

Preclinical diagnosis of AD 131

Meta-analysis of literature on imaging in AD 132

Alzheimer Disease Neuroimaging Initiative 132

Concluding remarks on imaging for diagnosis of AD 133

Diagnosis of MCI and prediction of AD 133

Diagnosis of MCI 133

Computer-Administered Neurophychological screen for MCI 133

Infrared eye-tracking technology to detect MCI 133

PET for detection of MCI 134

MRI for detection of MCI 134

Presymptomatic detection of AD 134

PredictAD project 135

Prediction of AD in patients with MCI 135

Combination of MMSE and a memory test for prediction of AD 135

Biochemical biomarkers in CSF for prediction of AD 135

Structural MRI biomarkers for prediction of AD 136

Magnetoencephalography for detection of MCI and AD 136

Concluding remarks about prediction of AD in MCI 137

Criteria for diagnosis of AD 137

Role of biomarkers in diagnosis of AD dementia 138

Ethical aspects of diagnostics for AD 138

Genetic testing for AD 138

Ethical issues of brain imaging in AD 139

Companies involved in diagnosis of AD 139

3. Management of Alzheimer Disease 141

Introduction 141

Cholinergic approaches 141

Mechanism of action of cholinesterase inhibitors 142

Choline and lecithin 143

Donepezil 144

Rivastigmine 145

Galantamine 146

Duration of treatment with ChE inhibitors 147

Comparative studies of ChE inhibitors 147

Donepezil versus rivastigmine 148

Donepezil versus galantamine 148

An assessment and future prospects of anticholinergic therapies 148

Neuroprotection in Alzheimer's disease 149

Memantine 150

Combination of memantine with ChE inhibitors 153

Monoamine oxidase inhibitors 153

Selegiline 154

Synaptoprotection in AD 154

Drugs for noncognitive symptoms in AD 154

Antidepressants 154

Antipsychotics 155

ChE inhibitors for behavioral and psychological disorders in AD 155

Concluding remarks and other drugs for agitation in AD 156

Sensory stimulation 156

Non-pharmacological treatments of AD 157

Management of memory loss in AD 157

Exposure to electromagnetic fields for treatment of AD 158

Application of electrical fields for improvement of cerebral function 158

High-frequency electromagnetic field treatment of AD 158

Vagal nerve stimulation 158

Cerebrospinal fluid shunting 159

Omental transposition 160

Microchip-based hippocampal prosthesis for AD 160

Nutritional therapies for AD 160

Axona 160

Cocktail of dietary supplements for AD 160

Docosahexaenoic acid 161

Magnesium 162

Nicotinamide for the treatment of AD 163

Omega-3 fatty acids 163

Preventing decline of mental function with aging and dementia 164

Prevention of Alzheimer disease 164

Mental training 165

Physical exercise 165

Higher level of conscientiousness and decreased risk of AD 166

Caloric restriction 166

Nutritional factors in prevention of AD 167

Grapes and red wine 167

Black and green teas 168

Caffeine 169

Drugs to prevent Alzheimer disease 169

Preimplantation genetic diagnosis of inherited Alzheimer disease 169

Presymptomatic detection of AD 170

Management of mild cognitive impairment 170

Management of Down syndrome 171

Guidelines for use of anti-dementia drugs in clinical practice 172

Donepezil and/or memantine 173

General care of the Alzheimer disease patients 173

Strategies for the management of Alzheimer disease 173

4. Research in Alzheimer Disease 175

Introduction 175

Animal models of Alzheimer disease 175

Lesional models 175

Cerebroventricular injection of A? in rats 175

Lentiviral vector-based models of amyloid pathology 176

AAV-mediated gene transfer to increase hippocampal A? 176

Transgenic mouse models 176

Quantitative assessment of amyloid load in transgenic models 178

In vivo magnetic resonance microimaging in transgenic models of AD 178

Transgenic model of AD with suppression of A? production 178

Transgenic AD11 anti-NGF mice 179

Genetically altered mice with deficiency of vesicular ACh transporter 179

Limitations of mouse models of Alzheimer disease 179

Cholesterol-fed rabbits as models for AD 180

Zebrafish model for AD 180

Transgenic invertebrate models of Alzheimer disease 181

Drosophila model of AD 181

Caenorhabditis elegans Alzheimer disease model 182

Cell systems for AD research 182

In vitro neuronal cell Lines 182

Single-gene expression system for use in cell culture 183

Transgenic cells 183

In silico models 184

Estimation of progression rates of Alzheimer disease 184

Clinical trial methods in Alzheimer disease 185

Molecular imaging as a guide to drug development 185

Use of MRI and PET in clinical trials 186

Cognitive-function assessment in clinical trials 186

Clinical trials in mild cognitive impairment 187

Research in AD as a basis for future therapies 187

Use of microarrays for studying pathogenesis of AD 187

Computational brain mapping in AD 187

Study of neurogenesis in AD 188

Study of 3D structure of A? 188

Solid-state NMR to study precursors of A? 188

Research in Alzheimer disease at academic centers 188

Role of NIH in AD research 189

NIH Clinical Trials Database for AD 189

Alzheimer Research Consortium 189

The National Institute on Aging and AD research 189

5. Drug Discovery & Development for Alzheimer Disease 191

Introduction 191

Categories of drugs in development for AD 191

Memory-enhancing drugs 193

Enhancing memory by drugs that block eIF2? phosphorylation 193

Drugs based on cholinergic approaches 193

AP2238 194

Butyrylcholinesterase inhibitors 194

Donepezil-tacrine hybrids 194

Drugs modulating gamma-aminobutyric acid receptors 195

Ganstigmina 195

Methanesulfonyl fluoride 195

Muscarinic receptor modulators 196

Muscarinic M1 agonists 196

Muscarinic M2 antagonists 197

Nicotine and nicotinic receptor modulators 197

Nicotine 197

Nicotinic receptor modulators 198

GTS21 199

Ispronicline 199

JWB1-84-1 200

Neuropeptide/neurotransmitters 200

Somatostatin release enhancers 200

Glutamate receptor modulators 200

Physiology and pharmacology of glutamate receptors 201

NMDA receptor ion channel complex 201

Metabotropic glutamate receptors 203

Glutamate receptor modulators as potential therapeutics for AD 204

Non-competitive NMDA modulators 205

AMPA modulators 205

Drugs affecting multiple neurotransmitters 206

Ensaculin 206

NS2330 206

RS-1259 206

Lecozotan 207

Vaccines for AD 207

Active immunization with A? 208

AN-1792 vaccine 208

Complications in clinical trials with AN-1792 208

Effects of A? vaccine on the brain 208

Strategies to avoid undesirable effect of A? vaccination 209

Passive immunization in AD 210

Passive immunization with MAbs 210

Delivery of the passive antibody directly to the brain 212

Systemic injection of MAbs to treat AD 213

Combination of A? immunotherapy and CD40-CD40L blockade 213

Shaping the immune responses elicited against A? 213

Delivery of AD vaccines 214

Gene vaccination 214

Modified A? nasal vaccine 214

Transdermal A? vaccination 214

Other vaccines for AD 215

Nasal vaccination with Proteosome? adjuvant 215

T-cell vaccination with glatiramer acetate adjuvant 216

Early start of immunotherapy to clear A? plaques 216

Reversal of cholinergic dysfunction by anti-A? antibody 216

Immune modulation via TRL9 to reduce A? 216

Mechanisms by which A? antibodies reduce amyloid accumulation in the brain 217

Perspectives on vaccines for AD 217

Companies involved in AD vaccines 219

Inhibition of amyloid precursor protein aggregation 220

Secretase modulators 220

Neuroprotection by ?-secretase cleaved APP 221

Inhibitors of ?-secretase 221

Inhibitors of ?-secretase 222

Amyloid-derived diffusible ligands 223

GABA receptor modulation by etazolate and APP processing 224

Depletion of serum amyloid P 224

Trojan-horse approach to prevent build-up of A? aggregates 224

Drugs that inhibit the formation of A? 225

22R-hydroxycholesterol 225

Acylaminopyrazole 226

Cadmium telluride nanoparticles prevent A? fibril formation 226

Cannabinoids 226

Chelation therapy for AD 227

Clioquinol and PBT2 227

Copper chelation by FKBP52 228

Zinc chelation from amyloid plaques 229

Next generation multifunctional chelating agents for AD 229

Heparin and its derivatives 229

A reassessment of the role of heparin in AD 229

Enoxaparin 230

Heparan sulfate 230

Imatinib mesylate 230

Laminin 231

NSAIDs 231

Flurbiprofen analogs with A?42-lowering action 232

Nitric oxide-donating NSAIDs 233

In vivo demonstration of the effects of NSAIDs on brain in AD 233

Paclitaxel 233

Phenserine 234

Tolserine 234

Platinum-based inhibitors of A? 235

Scyllo-cyclohexanehexol 235

Ubiquitin C-terminal hydrolase L1 235

Drugs to prevent the formation of NFTs 235

Tau suppression 236

ApoE4 as a therapeutic target in AD 237

Strategies to prevent deposits and enhance clearance of A? 237

4,5-dianilinophthalimide for disruption of A?1-42 fibrils 238

ABCA1 overexpression to lower amyloid deposits 239

Beta-sheet breakers 239

Blocking ApoE/A? interaction to reduce A? plaques 239

Clearance of A? across the blood-brain barrier 240

Enhanced PKC? activity promotes clearance of A? 240

Galantamine-induced A? clearance 240

Inhibitors of A? dehydrogenase 241

Intravenous immune globulin 241

Meptides 242

Monoclonal antibodies for removal of A? 242

Nanotechnology for removal of A? deposits 243

Role of matrix metalloproteinases in clearance of A? 243

SAN-61 for cleavage of fibril and soluble amyloid 243

Serum amyloid P component depletion 244

Small molecule DAPH for clearance of amyloid 244

Companies developing A?-directed therapeutics for AD 244

Antiinflammatory and antimicrobial drugs 246

Dapsone 246

Antimicrobial drugs against C. pneumoniae 246

PPAR-gamma agonists 246

Inhibitors of neuroinflammation 247

Cyclophosphamide 247

Etanercept 247

MW01-5-188WH 248

Antidiabetic drugs 248

Rosiglitazone 248

Pioglitazone 249

Nootropics 249

Acetyl-L-carnitine 249

Cerebrolysin 250

Ergot derivatives 250

Lisuride 250

Dihydroergocryptine 251

Neuroprotective effect drugs not primarily developed for AD 251

Antihypertensive drugs 252

Angiotensin-converting enzyme inhibitors 252

Angiotensin receptor blockers 252

Dimebon 252

Drugs acting on estrogen receptors 253

Estrogen 254

Raloxifene 254

Neurosteroids 255

Pregnenolone sulfate 255

Dehydroepiandrosterone 255

Lithium 256

MAO-B inhibitors 256

Ladostigil tartrate 256

Memoquin 257

Methylene blue 257

Nimodipine 257

Rapamycin 258

Statins 258

Testosterone 259

Valproic acid 260

Future prospects of neuroprotection in AD 260

Targeting Cdk5 pathway 261

Antioxidants 261

Colostrinin 262

Curcumin 262

Melatonin 263

Synthetic catalytic scavengers 263

Dehydroascorbic acid 263

Omega-3 fatty acids 264

Vitamins 264

Vitamin E as antioxidant 264

Vitamins to lower homocysteine 264

Folic acid 265

Aminopyridazines 265

Nanobody-based drugs for AD 265

Nitric oxide based therapeutics for AD 266

Nitric oxide mimetics 266

iNOS inhibitors for AD 266

Novel drugs for AD from natural resources 267

Berberine chloride 267

Centella asiatica 268

Ginko biloba 268

Huperzine-A 269

Hyperforin 270

Melissa officinalis 270

Nostocarboline derived from cyanobacteria 270

PTI-00703 271

Salvia 271

Securinega suffruticosa 271

Withania somnifera 271

ZT-1 272

Cholesterol and AD 272

ACAT inhibitors 273

Role of gene for cholesterol ester transfer protein 274

Cholesterol 24S-hydroxylase as a drug target for AD 274

Selectively increase of ApoA-I production 274

Neurotrophic factors 275

Activity-dependent neuroprotective protein 275

Brain derived neurotrophic factor 275

Insulin-like growth factor-1 275

Nerve growth factor 276

Neotrofin (AIT-082) 277

Limitations of the use of NTFs for AD 277

Role of serotonin modulators in AD 278

Xaliproden 278

5-HT1A receptor antagonists 278

5-HT6 antagonists 278

5-HT4 receptor agonists 279

PRX-03140 279

Cell therapy for AD 280

Stem cell transplantation for AD 280

Potential benefits of grafting NSCs in AD 280

NSCs improve cognition in AD via BDNF 281

Drugs for enhancing neuronal differentiation of implanted NSCs 281

Implantation of encapsulated cells for delivering NGF 281

Gene therapy for AD 281

ApoE gene therapy 282

FGF2 gene transfer in AD 282

Humanin gene therapy 282

Neprilysin gene therapy 282

NGF gene therapy 283

Targeting plasminogen activator inhibitor type-1 gene 284

Antisense approaches to AD 284

RNAi approaches to AD 285

Combined therapeutic approaches to AD 286

Drug delivery for Alzheimer disease 286

Delivery of thyrotropin-releasing hormone analogs by molecular packaging 286

Nanoparticle-based drug delivery for Alzheimer's disease 287

Transdermal drug delivery in Alzheimer's disease 288

Transdermal rivastigmine 288

Intranasal delivery of therapeutics for AD 288

Intranasal delivery of tacrine 288

Intranasal delivery of nerve growth factor to the brain 289

Circadian rhythms and timing of cholinesterase inhibitor therapy 289

Clinical trials for AD 289

Drugs for AD that were discontinued in clinical trials 294

Evaluation of clinical trials of AD 296

Monitoring of cognitive function during clinical trials 297

Drug discovery for AD 297

Drugs acting on signaling pathways 297

Activation of GTPase signaling by Cytotoxic Necrotizing Factor 1 297

Drugs to reverse inhibition of the PKA/CREB pathway in AD 297

Inhibition of the CD40 signaling pathway 298

JNK pathway as a target 299

Mitogen-activated protein kinase pathway as target 299

Protein kinase C activators 299

Electrophysiological detection of drug target for neuroprotection in early AD 299

Genomics-based drug discovery 300

High through screening for AD drug candidates 300

Proteomics and drug discovery for AD 301

Small molecule compounds binding to neurotrophin receptor p75NTR 302

Targeting Vav in tyrosine kinase signaling pathway 303

Novels targets/receptors for AD drug discovery 303

Activation of cerebral Rho GTPases 304

Activators of insulin-degrading enzyme 304

Blockade of TGF-?-Smad2/3 signaling in peripheral macrophages 304

Calcium channel blockers 305

Casein kinase 1 305

Cyclin-dependent kinase-5 305

Heat shock protein 90 inhibitors 306

Histone deacetylase 1 306

Inactivation of aph-1 and pen-2 reduces APP cleavage 306

NF-?B inhibitors 307

Kinases and phosphatases as targets for AD therapeutics 307

Neutral sphingomyelinase inhibitors 307

Phosphodiesterase inhibitors 308

Pin 1 as a target in AD 308

Protein phosphatase 5 as a neuroprotective in AD 309

Src homology-containing protein-1 inhibitors 309

Targeting GABAergic system 309

Pharmacogenomics of Alzheimer disease 309

Personalized therapy of AD 310

Genotyping and AD therapeutics 310

Biomarkers and companion diagnostics for AD 311

Regulatory aspects of drug development for AD 312

EMEA guidelines for drug development for AD 312

Concluding remarks and future prospects of drugs for AD 312

6. Markets & Finances of AD Care 315

Introduction 315

Pharmacoeconomics of treatment of AD 315

Quality of Life in relation to economics of AD 315

Costs associated with Alzheimer disease 315

Pharmacoeconomics of donepezil 316

Pharmacoeconomics studies using rivastigmine 316

Pharmacoenonomics studies using galantamine 317

A comparison of pharmacoenonomics outcomes with different ChE inhibitors 317

Pharmacoenonomics studies using memantine 318

Patterns of AD care in major markets 318

Care of AD patients in the US 318

Cost of care 318

Medicare and AD 319

Patterns of practice in AD care 320

Opinions of physicians' organizations on drugs for dementia 320

Care of AD patients in the UK 321

Cost of care 321

Patterns of practice in AD care 321

Retraction of NICE recommendations to NHS 322

Care of AD patients in Germany 323

Care of AD patients in France 323

Care of AD patients in Italy 324

Care of AD patients in Spain 324

Care of AD patients in Japan 324

Markets for AD diagnostics 325

Markets for AD therapeutics 325

Geographical markets for AD 325

Markets for currently approved drugs for AD 326

Markets for generic AD drugs 326

Future growth of AD market 327

Statins 327

Limitations of AD drug development by the biotechnology industry 327

Unmet needs in the management of AD 328

Drivers of AD markets 329

Increase of the aged populations 330

Increase in the number of approved drugs for AD 330

Limitations of the current therapies 330

Improvements in diagnosis 330

Increasing awareness of the disease 331

7. Companies 333

Introduction 333

Profiles of companies 333

Abbott Laboratories 334

AC Immune SA 335

Accera Inc 337

Actelion Ltd 338

Acumen Pharmaceuticals Inc 339

Addex Pharmaceuticals 340

Adlyfe Inc 341

Advanced Life Sciences 342

Affiris GmbH 343

Allon Therapeutics Inc 344

AlzProtect 345

Amgen Inc 346

Amorfix Life Sciences Ltd 347

Applied NeuroSolutions Inc 348

Archer Pharmaceuticals Inc 349

AstraZeneca 350

Athena Diagnostics Inc 351

Avera Pharmaceuticals Inc 352

Avid Radiopharmaceuticals Inc 353

Avineuro Pharmaceuticals Inc 354

Axon Neuroscience 355

Bayer Healthcare 356

Bayer Pharma AG 357

Baxter Healthcare International Inc 358

Bellus Health Inc 359

BioArctic Neuroscience AB 360

BiOasis Technologies Inc 361

BioE Inc 362

Boehringer Ingelheim GmbH 363

Bristol-Myers Squibb Company 364

BTG International Ltd 365

CALBIOCHEM 366

Cellzome AG 367

CEPHALON Inc 368

Ceregene Inc 369

Chiesi Farmaceutici SpA 370

Circadian Technologies Ltd 371

CoMentis Inc 372

Cortex Pharmaceuticals Inc 373

Cortica Neurosciences 374

Crossbeta Biosciences BV 375

Curaxis Pharmaceutical Corporation 376

Cyberonics Inc 377

Cytos Biotechnology AG 378

D-Pharm 379

Dainippon Sumitomo Pharma 380

Debiopharm SA 381

Diamedica Inc 382

Digilab BioVisioN GmbH 383

Ebewe Pharma GmbH 384

Eisai Co Ltd 385

Eli Lilly & Co 386

ENKAM Pharmaceuticals A/S 387

EnVivo Pharmaceuticals 388

EPIX Pharmaceuticals 389

Evotec AG 390

ExonHit Therapeutics SA 391

FluoroPharma Inc 392

Forest Laboratories Inc 393

Galantos Pharma GmbH 394

Galapagos Genomics 395

GE Healthcare Ltd 396

GlaxoSmithKline 397

H. Lundbeck A/S 398

Helicon Therapeutics Inc 399

Hoffmann-La Roche Ltd 400

Humanetics Corporation 401

Innogenetics NV 402

Intellect Neurosciences Inc 403

IntelliHep Ltd 404

Interleukin Genetics Inc 405

Intra-Cellular Therapies Inc 406

ItherX 407

JANSSEN Alzheimer Immunotherapy 408

Lay Line Genomics 409

Lexicon Genetics Incorporated 411

Maas BiolAB LLC 412

Medivation Inc 413

Merck & Co 414

Merz & Co GmbH 415

MIGENIX Inc 416

MindGenix Inc 417

Mindset BioPharmaceuticals Ltd 418

Mithridion Inc 419

MorphoSys AG 420

Myriad Genetics Inc 421

Neurimmune Holding AG 422

Neuro-Hitech Inc 424

Neurologix Inc 425

NeuroMolecular Pharmaceuticals 426

Newron Pharmaceuticals SpA 427

Neuronautics Inc 428

NeuroNascent Inc 429

NeuroNova AB 430

Neuroptix Corporation 431

NeuroSearch 432

Noscira 433

Novartis AG 434

NsGene 435

Nymox Corporation 436

Ortho-McNeil Neurologics Inc 437

Osta Biotechnologies Inc 438

Panacea Pharmaceuticals Inc 439

Pfizer Pharmaceutical Group 440

Pharmexa A/S 441

Pharnext SAS 442

Phytopharm Plc 443

Prana Biotechnology Limited 444

PrimaBiomed Ltd 445

Probiodrug AG 446

Proneuron Biotechnologies Ltd 447

ProteoTech Inc 448

Provista Life Sciences 449

Raptor Pharmaceuticals Corp 450

Reata Pharmaceuticals Inc 452

ReGen Therapeutics Plc 453

reMYND NV 454

Samaritan Pharmaceuticals Inc 455

Sanomune Inc 456

Sanochemi

To order this report:Drug and Medication Industry: Alzheimer disease - New drugs, markets and companies

Market Research Report

Check our

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Economist Conferences' The Pharma Summit 2012 to be Held on 9th February 2012, London

Tue, 31 Jan 2012 15:21:00 +0000

Economist Conferences' The Pharma Summit 2012 to be Held on 9th February 2012, London

PR Newswire

LONDON, January 31, 2012 /PRNewswire/ --

- Tweet your questions ahead of the Pharma Summit at @EC_PharmaSummit -

- New Speaker Confirmed - Stephen Whitehead, Chief Executive Officer, ABPI -

Economist Conferences is holding its 18^th Annual Pharma Summit 2012 in London on Thursday, 9^th February 2011. The event will be held in London at Hotel Russell, 1-8 Russell Square, Bloomsbury, from 8:30am to 5pm.

The Pharma Summit has become a key global event for the healthcare industry, attracting some of the most influential names in pharmaceuticals and healthcare. This year's theme 'Finding New Directions', will assess the difficult strategic choices facing the industry as R&D costs escalate and other more reliable revenue streams become increasingly attractive.

The Pharma Summit will bring together over 200 senior executives from the some of the world's top pharmaceutical companies, with a series of keynotes, panel discussions, interviews and debates. Tailored for its audience, discussion will focus on a number of topical issues and thought provoking sessions such as emerging healthcare models and the role pharma can play in them, the real implications of patient-centric healthcare and the scientific innovations that will transform the future of the industry.

To get the latest updates from The Pharma Summit, submit your questions, and to join in with the discussions on the day, make sure you are following us on Twitter @EC_PharmaSummit

Get access to some of the industry's leading experts including new speaker:

Simon Dingemans, Chief Financial Officer, GlaxoSmithKline
Sir Andrew Dillon, Chief Executive Officer, NICE
Anders Ekblom, Executive Vice-president, Global Drug Development, AstraZeneca
Freda Lewis-Hall, Chief Medical Officer and Executive Vice-president, Pfizer
Bruno Strigini, President, Europe/Canada, Merck & Co
Patrick Flochel, Partner, EMEIA Life Sciences Leader, Ernst and Young
Stephen Whitehead, Chief Executive Officer, Association of the British Pharmaceutical Industry
Theresa Heggie, Senior Vice-president, Global Commercial Operations, Shire HGT
John Pottage, Chief Scientific and Medical Officer, ViiV Healthcare
Wendy White, Founder and President, Siren Interactive
Andrew Baum, Managing Director, Citi
Simon Moroney, Chief Executive Officer, MorphoSys
Brian Griffin, Chief Executive Officer, Medco International
Nina Schwalbe, Managing Director, Policy and Performance, Global Alliance for Vaccines and Immunization
Tachi Yamada, Chief Medical and Scientific Officer, Executive Vice-president and Board Member, Takeda Pharmaceuticals International

A drinks reception will also follow the event in the Woburn Suite, Hotel Russell, where you can join Olympic, Paralympic and World Champions, who are representing the Dame Kelly Holmes Legacy Trust. This charity supports disadvantaged young people through mentoring from world class athletes, getting them fit for work and fit for life.

To find out more information and to register, please go to http://www.thepharmasummit.com, and complete the online form.

About Economist Conferences

Economist Conferences, a division of the Economist Intelligence Unit, is the leading provider of international forums for senior executives seeking new insights into strategic issues. These meetings include industry conferences, management events and government roundtables held around the world. As part of The Economist Group, the publisher of The Economist newspaper, Economist Conferences is a highly respected brand with a 163-year history and an unrivalled reputation for excellence and independence.

Each meeting organised by Economist Conferences delivers objective and informed analysis. Its meetings provide unusually high-level forums where senior executives can gain insights, exchange views and compare strategies.

This press release has been issued by M:Communications on behalf of The Economist Conferences' The Pharma Summit 2012.

For further information please contact Claire Dickinson or Hollie Vile at M:Communications, pharmasummit2012@mcomgroup.com, Tel: +44(0)20-7920-2360

Contact Information:
Helen Mulligan, Economist Conferences
E: helenmulligan@economist.com
Tel: +44(0)20-7576-8137

For further information on event registration, or to request an interview with any of the speakers at the Economist Conferences' The Pharma Summit 2012, contact Claire Dickinson or Hollie Vile at M:Communications.
E: pharmasummit2012@mcomgroup.com
Tel: +44(0)20-7920-2360

Economist Conferences' The Pharma Summit 2012 to be Held on 9th February 2012, London

Tue, 31 Jan 2012 15:21:00 +0000

Economist Conferences' The Pharma Summit 2012 to be Held on 9th February 2012, London

PR Newswire

LONDON, January 31, 2012 /PRNewswire/ --

- Tweet your questions ahead of the Pharma Summit at @EC_PharmaSummit -

- New Speaker Confirmed - Stephen Whitehead, Chief Executive Officer, ABPI -

To get the latest updates from The Pharma Summit, submit your questions, and to join in with the discussions on the day, make sure you are following us on Twitter @EC_PharmaSummit

Get access to some of the industry's leading experts including new speaker:

Simon Dingemans, Chief Financial Officer, GlaxoSmithKline
Sir Andrew Dillon, Chief Executive Officer, NICE
Anders Ekblom, Executive Vice-president, Global Drug Development, AstraZeneca
Freda Lewis-Hall, Chief Medical Officer and Executive Vice-president, Pfizer
Bruno Strigini, President, Europe/Canada, Merck & Co
Patrick Flochel, Partner, EMEIA Life Sciences Leader, Ernst and Young
Stephen Whitehead, Chief Executive Officer, Association of the British Pharmaceutical Industry
Theresa Heggie, Senior Vice-president, Global Commercial Operations, Shire HGT
John Pottage, Chief Scientific and Medical Officer, ViiV Healthcare
Wendy White, Founder and President, Siren Interactive
Andrew Baum, Managing Director, Citi
Simon Moroney, Chief Executive Officer, MorphoSys
Brian Griffin, Chief Executive Officer, Medco International
Nina Schwalbe, Managing Director, Policy and Performance, Global Alliance for Vaccines and Immunization
Tachi Yamada, Chief Medical and Scientific Officer, Executive Vice-president and Board Member, Takeda Pharmaceuticals International

To find out more information and to register, please go to http://www.thepharmasummit.com, and complete the online form.

About Economist Conferences

This press release has been issued by M:Communications on behalf of The Economist Conferences' The Pharma Summit 2012.

For further information please contact Claire Dickinson or Hollie Vile at M:Communications, pharmasummit2012@mcomgroup.com, Tel: +44(0)20-7920-2360

SOURCE Economist Pharma Summit

Warner Chilcott Sued for Denying Employees Overtime Pay

Mon, 30 Jan 2012 16:00:00 +0000

Warner Chilcott Sued for Denying Employees Overtime Pay

Federal Class Action Suit Charges Pharma Company with Violating Labor Law

PR Newswire

NEW YORK, Jan. 30, 2012 /PRNewswire/ -- Former pharmaceutical representative Timothy Brennan today filed a lawsuit in federal court in Manhattan against Warner Chilcott charging the drug corporation with illegally denying him compensation for overtime hours. The law firm of Joseph, Herzfeld, Hester & Kirschenbaum LLP represents Brennan. The suit charges that during his four-and-a-half years of employment, Brennan often worked in excess of 40 hours a week but received an annual salary without overtime pay. The New York class action was filed on behalf of Brennan and all other pharma reps who worked for Warner Chilcott in New York during the last six years.

New York overtime law requires that employees be paid time-and-a-half overtime when they work more than 40 hours in a week, unless they are specifically exempt.

Attorney Charles Joseph, a partner with Joseph, Herzfeld Hester & Kirschenbaum LLP, stated, "The US Department of Labor recognizes that pharmaceutical reps are not exempt from overtime pay under the Federal Fair Labor Standards Act (FLSA), and New York overtime law is consistent with the FLSA."

Joseph explained that the precedent for Brennan's claim was set in the U.S. Court of Appeals for the Second Circuit, which found that Novartis pharma reps were entitled to overtime compensation on the same basic grounds alleged against Warner Chilcott. (Novartis recently settled the overtime lawsuit for $99 million.) The Second Circuit issued a similar ruling in a case brought by pharma reps against Schering Plough, as have district courts in Connecticut and Illinois in cases against Boerrhinger Ingelehein and Abbott.

Brennan, who worked for the company in Manhattan, said, "For years, this company failed to pay representatives their earned overtime. This lawsuit holds them accountable."

"Our view is that Mr. Brennan and other Warner Chilcott reps are owed a great deal of money for working extraordinarily long hours with no additional compensation," Joseph said. "This is a chance to achieve justice for the reps."

For more information, call toll free (866) 348-7394 or visit www.pharmarepovertime.com.

Joseph, Herzfeld, Hester & Kirschenbaum LLP is a New York City employment law firm which has brought overtime cases on behalf of pharma reps since 2006, including lawsuits against the following companies: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers, Eli Lilly, GlaxoSmithKline, Hoffman-LaRoche, Johnston & Johnson, Merck, Pfizer, Sanofi-Aventis, and Schering-Plough.

SOURCE Joseph, Herzfeld, Hester & Kirschenbaum LLP

New Actavis / Bioton Alliance to Shake up Diabetes Market

Mon, 30 Jan 2012 11:43:00 +0000

New Actavis / Bioton Alliance to Shake up Diabetes Market

PR Newswire

Global Managed-Care Offering to Help Bring Down Treatment Costs for 366 Million Diabetics

WARSAW, Poland, Jan. 30, 2012 /PRNewswire-Asia/ -- Actavis and Bioton (WSE:BIO) announced today that they have formed a joint venture company for the development and registration of insulins, including analogue insulins. Within the framework of the joint-venture, Bioton will be responsible for the development and manufacture of insulin products, while Actavis will be granted an exclusive licence to commercialise those products under the Actavis brand throughout the European Union and the United States of America, as well as in Albania, Bosnia & Herzegovina, Croatia, Iceland, Japan, Kosovo, Lichtenstein, Macedonia, Montenegro, Norway, Serbia and Switzerland. In Poland, both companies will offer the insulin products under their respective brands, Bioton being a Polish company.

The announcement, at a press conference in Warsaw today, was made jointly by Ryszard Krauze, Chairman of the Supervisory Board of Bioton, and Claudio Albrecht, CEO of the Actavis Group and Chairman of the Actavis Board of Directors.

Actavis has agreed to remunerate Bioton with the aggregate amount of EUR 55.5 million, of which EUR 22.25 million at signing today. The remainder (EUR 33.25 million) will be paid in instalments in accordance with agreed milestones relating to the registration process involving recombined human insulin (RHI).

Based on the sales volumes estimated by the parties, the Actavis' revenues from the sale of the Insulins by Actavis into the markets in the initial period of 7 years from launch are expected to exceed EUR 1.5 billion. Pursuant to the agreement, the parties will share on an equal '50/50' basis the profits from the sale of the insulins performed by Actavis, as well as the development and registration costs related to Bioton insulins.

In addition to the above, the Bioton Group have also signed memoranda of understanding with Actavis for the sale of insulins in 24 additional territories, including Turkey and Australia. Actavis will pay an additional consideration of up to EUR 1,900,000, including EUR 1,000,000 at signing. Both parties expect that sales of Bioton's recombinant human insulin by Actavis into some of the additional territories shall commence on the turn of 2012 and 2013. The profits from the sale of the insulins in these additional territories will again be shared on an equal basis (50/50). Formal documentation of these arrangements is expected to be concluded in the following weeks.

Actavis CEO Claudio Albrecht believes the new alliance will create tremendous value for Actavis and Bioton and their respective shareholders. "The recombinant- and analogue insulins alone should add around EUR 900 million (USD 1.2 billion) to our enterprise value. Thanks to the collaboration agreement with Bioton, we will be among the leading manufacturers of insulin, including analogue insulins," predicted Albrecht.

Chairman of the Supervisory Board of Bioton S.A. Ryszard Krauze commented, "The cooperation with Actavis has a strategic importance for Bioton. We will jointly introduce modern insulins, including analogue insulins. For the last two years, we have been consistently increasing the sales of our products based on collaborations with leading global pharmaceutical firms such as Bayer HealthCare in China and GlaxoSmithKline in Russia. Today, we are pleased to welcome another large pharmaceutical firm to our group of partners - Actavis."

DIABETES - A GLOBAL EPIDEMIC

New data released by the International Diabetes Federation (IDF) indicates that more than 366 million people worldwide are living with diabetes. Due to poor diet and sedentary lifestyles, diabetes is rapidly becoming a global epidemic, and the number of diabetes patients is expected to rise to a figure in excess of 550 million by 2030. The World Health Organisation (WHO) projects that the global insulin market will grow from the present level of approximately USD 14 billion to USD 54 billion over that same period.

On average, a patient with diabetes type 2 takes almost 30 different medicines over the course of the disease. In light of that fact, the collaboration with Bioton represents a more fundamental and strategic concept in terms of treating diabetes, according to Claudio Albrecht.

"The diabetes idea for us is a much wider one than just promotion and sale of recombinant human insulin or insulin analogues," he said. "We are encountering competitor giants when it comes to insulin and we have to maximise the competitive advantages that we clearly have. Bioton's insulin products have a market presence of more than 10 years' standing, with an excellent safety and efficacy profile. This puts us in a situation where we can overcome more easily any potential doubts that key opinion leaders might have when it comes to biosimilars."

"Furthermore, we differ in one aspect very strongly in comparison with the originators," Albrecht added, highlighting the extensive range of generic type-2 oral diabetes drugs that Actavis already offers. Actavis' pipeline also includes high-value 'gliptin' products and several fixed dose combinations with Metformin.

COMPREHENSIVE CARE OFFERING

Albrecht noted that the opportunity to market a much broader portfolio in the context of diseases related to diabetes is a great one. "Actavis is the only company that can offer such a broad diabetes- and related diseases portfolio. We can tell payers that we cover the whole diabetes segment for a cost that is probably considerably less than they have been paying to date."

CEO of Bioton SA Sławomir Ziegert said, "For Bioton, the collaboration with Actavis will, in addition to bringing direct financial benefits, fuel faster expansion into high-margin markets, while supporting the implementation of our product synergy strategy and further growth in the area of cardio diabetology. Patients value highly the unique and comprehensive care offered by Bioton, a package which includes insulin, injectors, glucometers, oral diabetes medicines and an educational programme. All these elements provide an opportunity to extend our collaboration with Actavis in many markets around the world."

Contact

Actavis Group

Frank Staud

EVP Corporate Communication

Mobile: +41-79-230-95-78

E-Mail: fstaud@actavis.com

SOURCE　Actavis Group